INDEX OF SUBJECTS FOR VOLUME 51

Abiotrophia defectiva
  total knee arthroplasty infection, 899
Acinetobacter spp.
  antibiotic resistance, 1107
  population structure of hospital isolates, 1107
Actinobacillus actinomycetemcomitans
  detection by molecular methods, 1090
  macrophages in immune response, 581
  review of virulence factors and mechanisms, 1013
Adenocarcinoma, gastric, 777
Adherence
  auto-adhesion of *A. actinomycetemcomitans*, 1013
  Bartonella spp. to endothelial cells, 920
  Bartonella spp. to erythrocytes, 916
  B. cepacia to cystic fibrosis airway, 911
  E. coli in ligated colon loops of sheep, 755
  H. pylori to gastric epithelial cells, 295, 495
  M. genitalium to HEp-2 cells, 361
  M. pneumoniae to HEp-2 cells, 361
  properties of *S. aureus*, 747
Aeromonas hydrophila
  subtractive hybridisation studies, 461
Age
  changes in human faecal flora, 448
AIDS patients
  diagnosis of *T. gondii* encephalitis, 879
  dual *C. albicans* and *Cr. neoformans* fungaemia, 1135
Alveolar macrophages
  interaction with *S. pneumoniae*, 905
Alveolitis, allergic, 1117
Amoebiasis, 805
Amoxicillin
  prevalence of resistance in *H. pylori*, 786
  susceptibility of *H. pylori*, 705
Amphotericin B
  in invasive aspergillosis, 70, 95
  susceptibility of yeast bloodstream infections, 677
Amplified fragment length polymorphism (AFLP)
  typing of organisms from injecting drug users, 990
Amsel criteria, 795
Anaerobes
  heterogeneity of gram-positive cocci, 949
  intestinal, effect on *E. coli* O157:H7, 201
  secondary infections in skin lesions, 808
  in suppurative sialadenitis, 526
Ancylostoma braziliensis
  genital lesions, 805
Angiogenesis, *Bartonella*-related, 919
Animal models *see* Guinea-pig model; Mastomys; Mouse model; Pig model: rabbit model; Rat model; Sheep model
Animal reservoirs
  M. avium subsp. *paratuberculosis* and Crohn's disease, 3
Anthrax, 821
Antibiotic resistance
  amoxicillin, and *H. pylori*, 786
  azithromycin, and *H. pylori*, 786
  ciprofloxacin, and *H. pylori*, 786
  clarithromycin, and *H. pylori*, 705, 786
  clindamycin, and *H. pylori*, 786
  epidemic methicillin-resistant *S. aureus* (EMRSA), 516
  fusidic acid, and MRSA, 1113
  hospital isolates of *Acinetobacter* spp., 1107
  methicillin, and coagulase-negative staphylococci, 83
  methicillin, and *S. aureus* (MRSA), 283, 516, 1113
  metronidazole, and *H. pylori* , 705, 786
  penicillinase-encoding plasmids of *N. gonorrhoeae*, 799
  penicillin, in community-acquired pneumonia, 907
  population genetics of *B. fragilis*, 123
  prevalence in *H. pylori*, 786
  rifampicin, and MRSA, 1113
  S. pneumoniae, impact of vaccines, 102
  tetracycline, and *H. pylori*, 786
  tetracycline, and *L. monocytogenes*, 564
Antibiotics and other antimicrobial substances
  amphotericin B and aspergillosis, 70, 95
  antifungal-immunomodulatory therapy for aspergillosis, 70
  assessing multi-drug therapy for leprosy, 417
  azithromycin, in treatment of donovanosis, 803
  ceftriaxone, in treatment of donovanosis, 803
  chloramphenicol, and *M. hominis* meningo-encephalitis, 187
  clindamycin, and bacterial vaginosis, 796
  co-amoxiclav, and bacterial vaginosis, 796
  C. perfringens antibiotic-associated diarrhoea, 891
  fluconazole susceptibility of *Candida* spp., 105, 479
  fluoroquinolones, in community-acquired pneumonia, 907
  fluvastatin, and *C. albicans*, 105
  in fungaemic children, 110
  HAART (highly active antiretroviral therapy), 1135
  management of bacterial vaginosis, 796
  metronidazole, and bacterial vaginosis, 796
  oxacillin disk testing for CNS, 83
  penicillin, in community-acquired pneumonia, 907
  penicillin, susceptibility of *N. meningitidis*, 855
  pravastatin, and *C. albicans*, 105
  pyrazinamide, susceptibility testing of *M. tuberculosis*, 11, 42
  quinolones, in treatment of donovanosis, 803
  rapid susceptibility testing, 192
  role in community-acquired pneumonia, 907
  secondary infections in skin lesions, 808
  silver sulphadiazine, and *S. aureus*, 50
  susceptibility of *H. pylori*, 705
  susceptibility of yeast bloodstream infections, 677
  susceptibility of *Y. enterocolitica*-like strains, 56
  treatment of donovanosis, 803
  voriconazole susceptibility of *Candida* spp., 479
Antibodies
  against anthrax toxins, 821
  against *B. burgdorferi*, 641, 649
  against *B. canis*, 656
  against *E. coli*, 522, 1050
  against ehrlichiae in cattle, 326
  against group B streptococci, 595
  against hantavirus, 861
  against hepatitis C virus, 700
  against *H. pylori*, 238, 300
  against *M. genitalium*, 361
  against *M. pneumoniae*, 361
  against OspC from *Borrelia* spp., 731
  against *S. pneumoniae*, 837
  anti-mannan, 433
  in post-streptococcal glomerulonephritis, 589
Antigens
  A. actinomycetemcomitans, 1013
  B. abortus, 661
  B. afzelii, 731
  B. burgdorferi, 641, 649, 731
  B. garinii, 731
  B. pseudomallei, 1055
  C. botulinum, 813
  E. coli, 522, 1050
  group B streptococci, 595
  hantavirus, 861
  hepatitis C virus, 700
  in post-streptococcal glomerulonephritis, 589
  S. pneumoniae, 837
  superantigen of *A. actinomycetemcomitans*, 1013
  T. asahi, 423
Apoptosis
  effects of *C. albicans* on macrophages, 929
  effects of *H. pylori* on endothelial cells, 385
  macrophages by *L. longbeachae* , 159
  neutrophils, effects of influenza A virus and *E. coli*, 484
  neutrophils, role of respiratory burst, 484
  superantigen of *A. actinomycetemcomitans*, 1013
Appendicular taeniasis, 90
Arthroplasty, 899
Aspergillosis, 70, 95
Aspergillus spp.
  A. flavus, intracranial infection and therapy, 70
  A. fumigatus, melanin production, 189
  A. fumigatus, microsatellite analysis, 1128
  amphotericin B in invasive aspergillosis, 70, 95
Atherosclerosis, 623

Azithromycin
prevalence of resistance in *H. pylori*, 786
in treatment of donovanosis, 803

Bacillary angiomatosis, 915
Bacillus spp.
B. anthracis, phagocytosis of spores, 821
B. anthracis, role of anti-PA antibodies, 821
B. cereus, cellulitis, 278, 990
B. cereus, infection in injecting drug users, 278, 990, 1001
in microflora of heroin, 1001
Bactec® cultures
early identification of *M. tuberculosis* complex, 710
Bacteraemia
Bartonella spp., 915
F. necrophorum, 269
H. segnis, 635
P. aeruginosa, 615
thermo-tolerant *C. fetus*, 740
Bacterial vaginosis, 795
Bacteriocin
S. mutans, 941
Bacteroides spp.
B. forsythus, detection by molecular methods, 1090
B. fragilis, population genetics, 123
secondary infections in skin lesions, 808
Bancroftian filariasis, 804
Bartonella spp.
review of role in disease, 915
BD ProbeTec ET system, 895
Bifidobacteria
in human faecal flora, 448
Biochemical profiles
Y. enterocolitica-like strains, 56
Biofilm
mixed *C. albicans*/*S. epidermidis*, 344
P. aeruginosa, 910
Bite wounds, potential pathogens, 207
Black-pigmented bacteria
gingival keratinocyte activation, 27
Blood cultures
fungaemic children, 110
rapid identification of *S. aureus*, 530
yeast bloodstream infections, 677
BOOK REVIEWS
Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery (edited by P. J. Rosenthal), 360
Current Topics in Microbiology and Immunology, volume 257 (edited by G. Van der Goot), 715
Evolving Concepts in Sepsis and Septic Shock (edited by P. Q. Eichacker and J. Pugin), 532
Hepatitis C, Biomedical Research Reports (edited by T. J. Liang and J. H. Hoofnagle), 359
Infectious Causes of Cancer, Targets for Intervention (edited by J. J. Goedert), 358
Methods in Molecular Medicine, Cytomegalovirus Protocols (edited by J. Sinclair), 282
Methods in Molecular Medicine, *Mycobacterium tuberculosis* Protocols (edited by T. Parish and N. G. Stoker), 359
Methods in Molecular Medicine, Septic Shock – Methods and Protocols (edited by T. J. Evans), 282
Microbial Musings, A History of Microbiology (D. J. Bibel), 532
Viral Infections of the Nervous System, 2nd edition (R. T. Johnson), 359
Bordetella bronchiseptica
fimbriae and flagella, 557
TTGE sequence types, 557
Borrelia spp.
B. afzelii, OspC in serodiagnosis of Lyme borreliosis, 731
B. burgdorferi, genetic analysis of outer-surface protein C, 318
B. burgdorferi, DbpB as serodiagnostic antigen, 641
B. burgdorferi, enzyme-linked diagnostic assays, 641, 649
B. burgdorferi, OspC in serodiagnosis of Lyme borreliosis, 731
B. garinii, OspC in serodiagnosis of Lyme borreliosis, 731
Borreliosis, 318, 641, 649, 731
Brucella spp.
B. abortus, immune response to *GroEL* DNA vaccine, 20
B. abortus, GAPDH-induced Th1-type response and protective immunity, 661
B. canis, diagnosis of infection, 656
Burkholderia spp.
B. cepacia, in cystic fibrosis, 533, 911
B. cepacia complex genomovar-specific PCR, 937
B. mallei, type III secretion, 374
B. pseudomallei, characterisation of acapsular mutant, 539
B. pseudomallei, model of passive protection, 1055
B. pseudomallei, repetitive DNA element, 76
B. pseudomallei, type III secretion, 374
B. thailandensis, type III secretion, 374
monoclonal antibodies, 1055
subtractive hybridisation studies, 461, 463, 464, 465

Calymmatobacterium granulomatis see Klebsiella granulomatis
Campylobacters
C. coli, detection in faecal samples, 86
C. jejuni, detection in faecal samples, 86
thermo-tolerant *C. fetus* bacteraemia, 740
Cancer patients, paediatric, 601
Candida ID medium, 221
Candida spp.
activity of fluconazole and HMG CoA reductase inhibitors, 105
aetiology and susceptibility of bloodstream infections, 677
C. albicans, dual fungaemia with *Cr. neoformans*, 1135
C. albicans, fungaemic children, 110
C. albicans -induced cytokine expression, 672
C. albicans, interactions with macrophages, 929
C. albicans, mixed biofilm with *S. epidermidis*, 344
C. albicans, primary isolation media, 221
fluconazole susceptibility, 479
fungaemic children, 110
identification by RSCA, 468
infections in children with cancer, 601
mannanaemia and anti-mannan antibodies, 433
primary isolation media, 221
voriconazole susceptibility, 479
Candidosis, 433, 672
Capsule
A. actinomycetemcomitans, 1013
B. pseudomallei, 1055
Carcinoids
colonisation of Mastomys by *H. pylori*, 777
Carrion's disease, 915
Caspase pathway
in apoptosis of macrophages by *L. longbeachae*, 159
Cat-scratch disease, 915
Ceftriaxone
in treatment of donovanosis, 803
Cellulitis, 278, 990
Cervical screening for HPV, 606
Children
community-acquired pneumonia, 903
curliated *E. coli* and sudden infant death syndrome, 1009
establishment of streptococci in respiratory tract, 723
fungaemic, in Slovakia, 110
fungal infection in cancer patients, 601
impact of meningococcal C conjugate vaccine, 717
M. hominis meningo-encephalitis, 187
prevalence of *H. pylori*, 312
prevalence of resistant *H. pylori*, 786
S. mutans and *S. sobrinus* in dental plaque, 443
virulence of *E. coli* faecal strains, 548
Chlamydia
C. pneumoniae, association with atherosclerosis, 623
C. pneumoniae, epidemiology, 623
C. pneumoniae, pathogenesis, 623
C. psittaci, subtractive hybridisation studies, 462
C. trachomatis, review of screening tests, 1021
Chloramphenicol
in *M. hominis* meningo-encephalitis, 187
Cholera, 264
Chyluria, 804
Ciprofloxacin
prevalence of resistance in *H. pylori*, 786
Clarithromycin
susceptibility of *H. pylori*, 705, 786
Clindamycin
in bacterial vaginosis, 796
prevalence of resistance in *H. pylori*, 786
Clostridia
C. botulinum, anti-haemagglutinin MAbs, 286
C. botulinum, laboratory differentiation, 985
C. botulinum, mucosal immunisation with type C nonTox, 813
C. botulinum neurotoxin, 286
C. difficile in faecal flora, 448
C. difficile, toxin production and purine synthesis, 34
C. novyi infection in injecting drug users, 971, 978, 985, 990, 1001
C. perfringens, detection by PCR, 169

C. perfringens, diagnosis of antibiotic-associated diarrhoea, 891
C. perfringens, infection in injecting drug users, 985, 990, 1001
C. perfringens, laboratory differentiation, 985, 990
C. perfringens, toxins, 169, 891, 985, 990
C. septicum, laboratory differentiation, 985
C. sordellii, laboratory differentiation, 985
C. tetani, laboratory differentiation, 985
maximising growth from spores in clinical tissue/heroin, 985, 1001
recognition of species associated with wound infection, 985
Co-amoxiclav
in bacterial vaginosis, 796
Cochliomyia hominivorax
genital infection, 805
Colony-stimulating factors
immunomodulatory therapy for aspergillosis, 70
in periodontal disease, 27
priming of oral epithelial cells by IFN-γ, 626
Communicable Disease Control
severe illness in injecting drug users, 971, 978
Congo red binding
S. Typhimurium, 503
Contact lens-induced keratitis, 1063
Cordylobia anthropophaga
genital infections, 805
Crohn's disease, 3
Cryptococcus neoformans
bloodstream infections, 677
dual fungaemia with *C. albicans*, 1135
melanin production, 189
Culture medium
investigation into microflora of heroin, 1001
for *Mobiluncus* spp., 491
for primary isolation of yeasts, 221
Curlin
E. coli, 1009
Cystic fibrosis, 533, 909
Cytokines
C. albicans -induced expression, 672
gingival keratinocyte activation by black-pigmented bacteria, 27
immunomodulatory therapy for aspergillosis, 70
in localised aggressive periodontitis, 1013
priming of oral epithelial cells by IFN-γ, 626
in response to *L. pneumophila* infection, 225
Cytolethal distending toxin
A. actinomycetemcomitans, 1013

Decorin-binding protein B, 641
Dermatitis, atopic, 808
Dermatobium hominis
genital infections, 805
Dermatophytosis, 117
Diarrhoea
antibiotic-associated, 891
virulence of *E. coli* faecal strains in children, 548
Dihydrofolate reductase gene polymorphisms
P. carinii, 510
Dipstick assay
for typhoid fever, 173
DNA
in *B. abortus* vaccines, 20, 661
checkerboard hybridisation technique, 1090
detection of endodontic pathogens by molecular methods, 1090
detection of *H. pylori* in oral cavity, 764
identification of pathogenic fungi by RSCA, 468
molecular typing: overview, 7
molecular typing of *H. influenzae*, 399
molecular typing of *V. cholerae*, 392
population genetics of *B. fragilis*, 123
RAPD analysis of *Acinetobacter* spp., 1107
repetitive element in *B. pseudomallei*, 76
subtractive hybridisation studies, 459
vaccines against HSV-1, 350
Dogs
bites, potential pathogens, 207
diagnosis of *B. canis* infection, 656
Donovan bodies, 802
Donovanosis, 802
Dracunculus medinensis infection, 804
Drug users *see* Heroin; Injecting drug users
Duodenal ulcer disease, 300, 851

Eczema herpeticum, 808
Ehrlichia phagocytophila
antibodies in cattle, 326
Eikenella corrodens
induction of ICAM-1, 1080
Elephantiasis, 804
ELISA
antibodies in post-streptococcal glomerulonephritis, 589
antibodies to ehrlichiae, 326
diagnosis of *C. perfringens* antibiotic-associated diarrhoea, 891
indirect, diagnosis of *B. canis* infection, 656
for Lyme borreliosis, 641, 649, 731
Encephalitis, 879
Endocarditis, 915
Endodontic pathogens
detection by molecular methods, 1090
Endothelial cells
adherence of *S. aureus*, 747
effect of *H. pylori*, 385
interaction with *Bartonella* spp., 920
α-Enolase
from *S. pneumoniae*, 837
Enterococcus faecalis
rapid antimicrobial susceptibility testing, 192
Enterotoxins
C. perfringens, 169, 891
Entamoeba histolytica
genital infections, 805
Enzyme immuno-assay (EIA)
screening test for *C. trachomatis*, 1021
Epidemiology
carriage of *S. pneumoniae*, 99
C. pneumoniae and atherosclerosis, 623
epidemic syphilis, 800
fatal case of cholera, 264
F. necrophorum infections, 269
meningococcal serogroup C disease, 717
molecular, *B. cepacia* complex infection, 533
molecular, tuberculosis, 273
N. gonorrhoeae infection, 798
severe illness in injecting drug users, 971, 978, 990
sexually transmitted diseases, 793
typing human isolates of group B streptococci, 595
Epidermis
model of cutaneous candidosis, 672
Epidydimitis, tuberculous, 804
Epidydimo-orchitis, 804
Epithelial cells
adhesion of *M. genitalium*, 361
adhesion of *M. pneumoniae*, 361
gastric, adherence of *H. pylori*, 495
gingival keratinocyte activation by black-pigmented bacteria, 27
induction of ICAM-1 by *E. corrodens*, 1080
intestinal, elimination of *S. enterica*, 13
invasion of HEp-2 cells by *P. alcalifaciens*, 682
oral, priming by IFN-γ, 626
Erythrocytes
in infection by *Bartonella* spp., 915
interaction with *Y. pestis*, 150
Escherichia coli
AE lesions in ligated colon loops of sheep, 755
antibody production in pregnancy, 522
attaching and effacing (AEEC), 755, 1041
bacterial translocation in liver-resected rats, 687
β-D-glucuronidase-positive, clonal structure, 405
cell-detaching (CDEC), 548
curliated, and sudden infant death syndrome, 1009
effect of organic acids on O157:H7, 201
enteroaggregative (EAEC), 548
enterohaemorrhagic (EHEC), 143, 201, 336, 1032, 1050
enteropathogenic (EPEC), 548
hyper-toxigenic enterohaemorrhagic (HT-EHEC), 336
LPS–antibody cross-reactions, 1050
necrotoxic (NTEC), 548
novel combination of virulence factors, 1041
rapid antimicrobial susceptibility testing, 192
respiratory burst and neutrophil survival, 484
Shiga toxigenic (STEC), 332, 405, 548, 755
sorbitol-fermenting, 713
subtractive hybridisation studies, 461, 464
urinary tract infections, 192
uropathogen virulence genes, 138
variation in persistence of O157:H7 in lambs, 1032
verotoxigenic (VTEC), 143, 201, 522, 713
verotoxin receptors on bovine epithelium, 143

virulence of faecal strains in children, 548
Essential oils, plant
effect on *L. monocytogenes*, 567
Exophiala (*Wangiella*) *dermatidis*
melanin production, 189

Faeces
C. difficile and bacterial population, 448
changes in flora with age, 448
detection of *C. jejuni* and *C. coli*, 86
diagnosis of *C. perfringens* antibiotic-associated diarrhoea, 891
virulence of *E. coli* strains in children, 548
Fc-binding protein
A. actinomycetemcomitans, 1013
Fibrinogen
adherence of *S. aureus*, 747
Fibronectin
adherence of *S. aureus*, 747
Filariasis, 804
Filtration-enrichment culture method, 86
Fimbriae
B. bronchiseptica, 557
Flagella
Bartonella spp., 916
B. bronchiseptica, 557
H. pylori, 958
Flow cytometry
rapid antimicrobial susceptibility testing, 192
Fluconazole
activity against *C. albicans*, 105
susceptibility of *Candida* spp., 479
susceptibility of yeast bloodstream infections, 677
Flukes, 803
Fluorescence assay *see* Indirect immunofluorescence assay
Fluoroquinolones
in community-acquired pneumonia, 907
Fluvastatin
activity against *C. albicans*, 105
Food
transferable tetracycline resistance of *L. monocytogenes*, 564
Fungaemia
Candida spp., 601, 677
children in Slovakia, 110
dual *C. albicans* and *Cr. neoformans*, 1135
yeasts; aetiology and antifungal susceptibility, 677
Fungi
identification by RSCA, 468
infection in children with cancer, 601
Funiculitis, 804
Fusidic acid
resistance of MRSA, 1113
Fusobacterium spp.
F. necrophorum, bacteraemia, 269
F. necrophorum infections in England and Wales, 269
secondary infections in skin lesions, 808
in suppurative sialadenitis, 526

Gardnerella vaginalis
diagnosis and management of disease, 795
Gastric antrum
prevalence of *H. pylori*, 764
Gastric cancer, 300
Gastritis, 238, 300
Genes
16S rRNA sequencing of *H. segnis*, 635
18-kDa, of *M. leprae* in PCR, 417
analysis of *B. burgdorferi* in Taiwan, 318
analysis of *V. cholerae*, 392
antibiotic susceptibility of *H. pylori*, 705
applications of genetic typing for *N. gonorrhoeae*, 798
B. abortus GroEL heat-shock gene, 20
B. cepacia complex genomovar-specific PCR, 937
B. cepacia complex infection, 533
B. pseudomallei type III secretion, 374
clonal structure of GUD$^+$ STEC, 405
comparative genomics, 7
DbpB in serodiagnosis of Lyme borreliosis, 641
dihydrofolate reductase polymorphisms of *P. carinii*, 510
diversity of TT virus, 455
DNA-based vaccines against HSV-1, 350
flbA in motility, virulence and urease activity of *H. pylori* and *P. mirabilis*, 958
genotyping of group B streptococci, 595
genotyping of *H. alvei*, 575
genotyping of hepatitis C virus, 700
genotyping of *N. meningitidis* serogroup C, 717
H. pylori genotypes and duodenal ulcer disease, 851
identification of thermo-tolerant *C. fetus* bacteraemia, 740
microsatellite analysis of *A. fumigatus*, 1128
molecular characterisation of EMRSA-15 and EMRSA-16, 516
new variant in YMDD motif of hepatitis B virus, 695
non-adhesion virulence of *H. pylori*, 495
PCR detection of *mecA* in CNS, 83
PCR identification of *S. intermedius*, 178
population genetics of *B. fragilis*, 123
repetitive DNA element in *B. pseudomallei*, 76
salmonella invasion and virulence, 247
screening probe for *C. trachomatis*, 1021
sorbitol-fermenting verocytotoxigenic *E. coli*, 713
subtractive hybridisation studies, 461
tn *phoA* mutants of *P. alcalifaciens*, 682
TTGE sequence types in *B. bronchiseptica*, 557
uropathogen virulence, in *E. coli*, 138
Glomerulonephritis, post-streptococcal, 589
Glucuronoxylomannan antigen
T. asahi, 423
Glyceraldehyde-3-phosphate-dehydrogenase of *B. abortus*, 661
Gram-positive anaerobic cocci (GPAC) demonstration of heterogeneity, 949
Granuloma, pulmonary, 131
Granulomatous hepatitis, 915
Guinea-pig model
effect of lactoferrin feeding on antifungal response, 844
maternofetal transmission of *T. gondii*, 871
pulmonary granulomas, 131
Guinea worm infection, 804

HAART (highly active antiretroviral therapy), 1135
Haemagglutinins
C. botulinum, 286
Haemolysin
S. enterica serovar Typhimurium, 503
Haemolytic uraemic syndrome, 522
Haemophilus spp.
H. influenzae, community-acquired pneumonia in children, 903
H. influenzae, molecular typing of Indian isolates, 399
H. influenzae, in suppurative sialadenitis, 526
H. segnis, 16S rRNA sequencing, 635
H. segnis, bacteraemia, 635
Hafnia alvei
phenotypic and genotypic properties, 575
Hantavirus
serological study of infection, 861
Helicobacter pylori
adhesion of coccoid form, 295
antibodies to VacA/CagA in Chileans, 300
biological activity of LPS, 771
colonisation and carcinoid formation in Mastomys, 777
detection in oral cavity, 764
effects on endothelial cells, 385
flagella, 958
gastric infection in miniature pigs, 238
gastric mucosal density, 305
genotypes and duodenal ulcer disease, 851
interleukin-8 induction, 295
non-adhesin virulence genes, 495
prevalence in children, 312
prevalence of resistant isolates in children, 786
role of *flbA* in motility, virulence and urease activity, 958
subtractive hybridisation studies, 461
susceptibility to peroxidase system, 231
urease activity, 231
Hepatitis
granulomatous, 915
peliosis, 915, 920
Hepatitis B virus
new variant in YMDD motif, 695
Hepatitis C virus
genotypes in Jordan, 700
serological diagnosis, 700
Heroin
investigation for spore-forming organisms, 978, 985, 990
optimal examination of microflora, 1001
see also Injecting drug users
HIV infection
bacterial vaginosis and, 797

with dual *C. albicans* and *Cr. neoformans* fungaemia, 1135
interaction with pneumococcal infections and alveolar macrophages, 906
P. carinii carriage with, 611
virulence of *C. albicans* isolate, 929
Hookworms, 805
HPV (human papillomaviruses)
rapid PCR screening method, 606
HSV-1 (herpes simplex virus type 1)
DNA-mediated immunisation, 350
Hybridisation studies
checkerboard, detection of endodontic pathogens, 1090
subtractive, applications, 459
suppression subtractive, 461
Hydrocoele, 804

ICAM-1 (intercellular adhesion molecule 1)
induction by *E. corrodens*, 1080
in periodontal disease, 27
Immune response
cytokines in cutaneous candidosis, 672
effect of lactoferrin feeding on host antifungal response, 844
to *A. actinomycetemcomitans*, 581, 1013
to *B. abortus*, 20, 661
to *L. pneumophila*, 225
to *S. pneumoniae*, 101, 837

Immunisation
against *N. meningitidis* serogroup C, 717
guinea-pigs against *T. mentagrophytes*, 844
mice against *B. abortus*, 20, 661
mice against *C. botulinum*, 813
mice against HSV-1, 350
mice against hyper-toxigenic EHEC, 336
mice against *M. avium*, 1071
Immunocompromised patients, 611, 740, 1135
Immunoglobulins
IgM, in serodiagnosis of Lyme borreliosis, 731
Immunomodulatory therapy
for aspergillosis, 70
Indirect immunofluorescence assays
adhesion and inhibition of *M. genitalium*, 361
adhesion and inhibition of *M. pneumoniae*, 361
antibodies to ehrlichiae, 326
serological study of hantavirus infection, 861
Infection control
molecular typing: overview, 7
severe illness in injecting drug users, 971, 978
Influenza A virus
respiratory burst and neutrophil survival, 484
Injecting drug users
B. cereus cellulitis, 278, 990
infection with *C. novyi* and other spore-forming organisms, 971, 978, 985, 990, 1001
management of outbreak of infection, 971, 978
outbreak of severe illness, 971, 978, 985, 990
Interferon-γ (IFN-γ)
priming of oral epithelial cells, 626
in response to *L. pneumophila* infection, 225
Interleukins
IL-8, and gingival keratinocyte activation, 27
IL-8, and *H. pylori* adhesion, 295
IL-8, priming of oral epithelial cells by IFN-γ, 626
IL-12-expressing plasmid, 661
International *Burkholderia cepacia* Working Group (IBCWG), 537
Itraconazole
susceptibility of yeast bloodstream infections, 677

Jaundice, obstructive, 687

Keratitis, contact lens-induced, 1063
Kerion, 808
Klebsiella spp.
K. granulomatis, recent advances on donovanosis, 803
K. pneumoniae, rapid antimicrobial susceptibility testing, 192
K. pneumoniae, subtractive hybridisation studies, 461
Knee arthroplasty, 899

Lactobacilli
in bacterial vaginosis, 795, 798
in human faecal flora, 448
Lactoferrin
effect of feeding on host antifungal response, 844
Lamivudine therapy
new variant in YMDD motif of hepatitis B virus, 695
Larva currens lesions, 805
Larva migrans lesions, 805
Lectins
iectin-like substance of *E. corrodens*, 1080
Legionella spp.
L. longbeachae, apoptosis of macrophages, 159
L. pneumophila, in community-acquired pneumonia, 907
L. pneumophila, IFN-γ-mediated resistance, 225
Leishmania donovani
genital infection, 805
NADH-oxidase, NADPH-oxidase and myeloperoxidase activity in visceral leishmaniasis, 832
Leishmaniasis, 805, 832
Leprosy, 417, 805
Leucotoxin
A. actinomycetemcomitans, 1013
Ligase chain reaction (LCR)
early identification of *M. tuberculosis* complex, 710
screening test for *C. trachomatis*, 1021
Ligated intestinal loop technique, 755
Lipopolysaccharide (LPS)
A. actinomycetemcomitans, 1013
B. pseudomallei, 1055
E. coli, 1050
H. pylori, biological activity, 771
priming of oral epithelial cells by IFN-γ, 626
Lipoteichoic acids
priming of oral epithelial cells by IFN-γ, 626
Listeria monocytogenes
effects of plant essential oils, 567
listeriolysin O production, 567
phosphatidylcholine-specific production, 567
subtractive hybridisation studies, 461
transferable tetracycline resistance, 564
Listeriolysin O production, 567
Liver resection
bacterial translocation, 687
Lyme borreliosis, 318, 641, 649, 731
Lymph scrotum, 804

Macrophages
in *A. actinomycetemcomitans* -induced immune response, 581
alveolar, interaction with HIV infection, 906
alveolar, interaction with *S. pneumoniae*, 905
apoptosis by *L. longbeachae*, 159
effects of exposure to *C. albicans*, 929
killing of *T. mentagrophytes*, 844
phagocytosis of anthrax spores, 821
Mannan
antibodies against, 433
Mannanaemia, 433
Mastomys
colonisation by *H. pylori*, 777
Media *see* Culture medium
Melanins
in fungal pathogens, 189
Meningococcal disease, 855, 1102
Meningococcus *see Neisseria meningitidis*
Meningo-encephalitis, 187, 915
Methicillin
epidemic methicillin-resistant *S. aureus* (EMRSA), 516
resistance, in coagulase-negative staphylococci, 83
resistant *S. aureus* (MRSA), 283, 516, 1113
Metronidazole
in bacterial vaginosis, 796
susceptibility of *H. pylori*, 705, 786
Micrococcus luteus
resuscitation promoting factor (Rpf), 92
Microsatellite analysis
A. fumigatus, 1128
Milk
M. avium subsp. *paratuberculosis* and Crohn's disease, 3
Mobiluncus spp.
in bacterial vaginosis, 795
liquid culture media, 491
Molecular typing: overview, 7
Monoclonal antibodies
against *B. pseudomallei*, 539, 1055
against *C. botulinum* haemagglutinin, 286
against melanins, 189

Monocytes
NADH-oxidase, NADPH-oxidase and myeloperoxidase activity in visceral leishmaniasis, 832
Mortality, prediction index, 615
Motility
H. pylori, 958
P. mirabilis, 958
Mouse model
colonisation by ureaplasmas, 866
C. pneumoniae and atherosclerosis, 623
DNA-mediated immunisation against HSV-1, 350
Hyper-toxigenic EHEC infection, 336
IFN-γ-mediated resistance to *L. pneumophila*, 225
immune response to *B. abortus*, 20, 661
macrophages in *A. actinomycetemcomitans*-induced immune response, 581
mucosal immunisation against *C. botulinum*, 813
passive protection against *B. pseudomallei*, 1055
resistance to *M. avium* infection, 1071
virulence of *S. prolificans*, 924
Multi-locus sequence typing (MLST)
epidemic meningococcal disease isolates, 1102
Mushroom worker's lung, 1117
Mutacins
phylogenetic lineages of *S. mutans*, 941
Mycobacteria
early identification of *M. tuberculosis* complex, 710
isolation, and resuscitation promoting factor (Rpf), 92
M. avium, GroES and protection in mice, 1071
M. avium subsp. *paratuberculosis* and Crohn's disease, 3
M. bovis BCG, granulomatogenic activity, 131
M. leprae, assessing multi-drug therapy for leprosy, 417
M. leprae, genital lesions, 805
M. tuberculosis complex, direct detection, 895
M. tuberculosis, molecular epidemiology, 273
M. tuberculosis, pyrazinamide susceptibility testing, 11, 42
subtractive hybridisation studies, 462, 465
Mycolates
in granuloma induction, 131
Mycoplasmas
M. genitalium, adhesion and inhibition assay, 361
M. hominis, in bacterial vaginosis, 795
M. hominis meningo-encephalitis, 187
M. pneumoniae, adhesion and inhibition assay, 361
M. pneumoniae, community-acquired pneumonia in children, 903
Myelitis, 915
Myeloperoxidase
activity in visceral leishmaniasis, 832
Myiasis, 805

NADH-oxidase/NADPH-oxidase
activity in visceral leishmaniasis, 832
Nasopharynx
establishment of streptococci in infants, 723
Neisseria spp.
N. gonorrhoeae, applications of genetic typing, 798
N. gonorrhoeae, subtractive hybridisation studies, 461, 465
N. meningitidis, epidemic wave of disease, 1102
N. meningitidis, fatal outcome from disease, 855
N. meningitidis, serogroup C conjugate vaccine, 717
N. meningitidis, strain displacement, 1102
N. meningitidis, subtractive hybridisation studies, 461, 465
Neurotoxin
C. botulinum, 286, 813
Neutrophils
apoptosis, effects of influenza A virus and *E. coli*, 484
Nitric oxide (NO)
in *Salmonella* -infected epithelial cells, 13

Onchocerciasis, 804
Opa-typing
N. gonorrhoeae, 799
Oral bacteria
A. actinomycetemcomitans, 1013
canine, 207
detection of endodontic pathogens by molecular methods, 1090
establishment of streptococci in infants, 723
gingival keratinocyte activation by black-pigmented bacteria, 27
H. pylori in dental plaque, 764
P. anaerobius-specific PCR, 1097
S. mutans and *S. sobrinus* in dental plaque, 443
Organic acids
effect on *E. coli* O157:H7, 201
Oroya fever, 916
Osteomyelitis, 915
Oxacillin
disk susceptibility testing for CNS, 83

Paenibacillus macerans
in microflora of heroin, 1001
Paper smear method, 606
Paracoccidioides brasiliensis
melanin production, 189
Parotid gland infection, 526
Pathogenicity islands
subtractive hybridisation studies, 461

PCR
assessing multi-drug therapy for leprosy, 417
B. cepacia complex genomovar-specific, 937
carriage of *P. carinii*, 611
characterisation of Shiga toxigenic *E. coli*, 332
cytokine expression in cutaneous candidosis, 672
detection of *C. jejuni* and *C. coli* in faeces, 86
detection of *C. perfringens*, 169
detection of endodontic pathogens, 1090
detection of *H. pylori*, 764
detection of *mecA* gene in CNS, 83
detection of *S. mutans* and *S. sobrinus*, 443
heterogeneity of gram-positive anaerobic cocci, 949
H. pylori numbers in gastric mucosa, 305
identification of dermatophyte fungi, 117
identification of *S. intermedius*, 178
identification of *Thermoactinomyces* spp., 1117
identification of thermo-tolerant *C. fetus* bacteraemia, 740
maternofetal transmission of *T. gondii*, 871
population genetics of *B. fragilis*, 123
prevalence of *H. pylori* in children, 312
rapid screening method for HPV, 606
reverse transcription (RT-PCR), 417, 672
screening test for *C. trachomatis*, 1021
specific for *P. anaerobius*, 1097
stage-specific primers for diagnosis of *T. gondii* encephalitis, 879
Peliosis hepatitis, 915, 920
Pelvic inflammatory disease, 1021
Penicillin
in community-acquired pneumonia, 907
susceptibility of *N. meningitidis*, 855
Penicillinase
N. gonorrhoeae, 799
Penicillium marneffei
melanin production, 189
Peptidoglycans
priming of oral epithelial cells by IFN-γ, 626
Peptostreptococcus spp.
demonstration of heterogeneity, 949
P. anaerobius, specific PCR, 1097
P. micros, detection by molecular methods, 1090
in suppurative sialadenitis, 526
Periodontal disease, 27, 1013
Periodontitis
canine, 207
localised aggressive (LAP), 1013
Peroxidase system
susceptibility of *H. pylori*, 231
Phagocytosis
anthrax spores by macrophages, 821
lactoferrin feeding and host antifungal response, 844
Phosphatidylcholine-specific production, 567
Pig model
H. pylori gastric infection, 238
Placenta growth factor, 920
Plasmids
antibiotic resistance of *N. gonorrhoeae*, 799
in DNA vaccine formulation, 661
interleukin-12-expressing, 661
sorbitol-fermenting verocytotoxigenic *E. coli*, 713
Plasminogen
binding by *S. pneumoniae a*-enolase, 837
Platelets
adherence of *S. aureus*, 747
Pneumococcus *see Streptococcus pneumoniae*
Pneumocystis carinii
carriage in immunocompromised patients, 611
dihydrofolate reductase gene polymorphisms, 510

Pneumonia
Candida spp., 601
community-acquired, 903, 907
H. influenzae, 903
M. pneumoniae, 903
respiratory syncytial virus, 903
S. pneumoniae, 903, 907
Pneumonitis, hypersensitivity, 1117
Poison ivy, 808
Porphyromonas spp.
P. endodontalis, detection by molecular methods, 1090
P. gingivalis, detection by molecular methods, 1090
P. gingivalis, gingival keratinocyte activation, 27
P. gingivalis, subtractive hybridisation studies, 463
secondary infections in skin lesions, 808
in suppurative sialadenitis, 526
Praomys natalensis see Mastomys
Pravastatin
activity against *C. albicans*, 105
Pregnancy
bacterial vaginosis in, 797
VTEC O157 infection in, 522
Prevotella spp.
in bacterial vaginosis, 795
P. intermedia, gingival keratinocyte activation, 27
secondary infections in skin lesions, 808
in suppurative sialadenitis, 526
Protease
activity of *P. aeruginosa*, 1063
IgA1, production by streptococci in infants, 723
Protein
B. abortus glyceraldehyde-3-phosphate-dehydrogenase, 661
of *B. pseudomallei*, as immunogens, 1055
decorin-binding, of *B. burgdorferi*, 641
exoproteins of *S. aureus*, 50
fc-binding, of *A. actinomycetemcomitans*, 1013
GroES, in protection against *M. avium* infection, 1071
H. pylori VacA/CagA, 300
outer-membrane, of *S. enterica*, 247
outer-surface, of *B. burgdorferi*, 318
outer-surface C (OspC), of *Borrelia* spp., 731
streptococcal M peptides, 589
surface, of *M. genitalium*, 361
surface, of *M. pneumoniae*, 361
Proteus mirabilis
rapid antimicrobial susceptibility testing, 192
role of *flbA* in motility, virulence and urease activity, 958
Providencia alcalifaciens
invasiveness of Tn *phoA* mutants, 682
Pseudomonas aeruginosa
bacteraemia, index predicting mortality, 615
biofilm, 910
community-acquired sacro-iliitis, 620
in cystic fibrosis, 910
pathogenicity islands, 910
quorum-sensing system, 1063
rapid antimicrobial susceptibility testing, 192
subtractive hybridisation studies, 464, 465
virulence factors in keratitis, 1063
Psoriasis, 808
Public health issues
M. avium subsp. *paratuberculosis* and Crohn's disease, 3
severe illness in injecting drug users, 971, 978
Pulmonary granulomas, 131
Pulsed-field gel electrophoresis (PFGE)
analysis of epidemic meningococcal disease isolates, 1102
analysis of *V. cholerae* in Iran, 392
epidemiology of cholera in Japan, 264
genotyping group B streptococci, 595
multiresistant MRSA, 1113
Purine synthesis
C. difficile, 34
Pyrazinamide
susceptibility testing, *M. tuberculosis*, 11, 42

Quinolones
in treatment of donovanosis, 803
Quintan fever, 921
Quorum-sensing system
P. aeruginosa, 1063

Rabbit model
C. pneumoniae and atherosclerosis, 623
RAPD fingerprinting
hospital isolates of *Acinetobacter* spp., 1107
RAPIDEC staph™ test, 530
Rat model
liver resection and bacterial translocation, 687
Respiratory burst
neutrophil apoptosis, 484
in visceral leishmaniasis, 832
Respiratory syncytial virus (RSV)
community-acquired pneumonia in children, 903
Respiratory tract infections
establishment of streptococci in infants, 723
IFN-γ-mediated resistance to *L. pneumophila*, 225
review, 903
Thermoactinomyces spp. in mushroom worker's lung, 1117
see also specific conditions and organisms
Restriction fragment-length polymorphism (RFLP) analysis
characterisation of EMRSA-15 and EMRSA-16, 516
molecular epidemiology of tuberculosis, 273
Resuscitation promoting factor (Rpf), 92
Retinitis, stellar, 915
Rifampicin
resistance of MRSA, 1113
RSCA (reference strand-mediated conformational analysis)
identification of pathogenic fungi, 468

Sabouraud-chloramphenicol agar, 221
Sacro-iliitis, 620
Salmonellae
S. enterica, Congo red binding, 503
S. enterica, elimination by intestinal epithelial cells, 13
S. enterica, haemolysin production, 503
S. enterica, invasion, 247
S. enterica, outer-membrane proteins, 247
serotype Enteritidis, 13
serotype Typhimurium, 247, 503
S. typhi, dipstick assay, 173
subtractive hybridisation studies, 461, 464, 465
Scabies, 808
Scedosporium prolificans
virulence of strains from different origins, 924
Schistosoma haematobium
genital infections, 803
Schistosomiasis, 803
Screening tests
C. trachomatis, 1021
Screw-worm, 805
Serology
antibodies to ehrlichiae in cattle, 326
diagnosis of *B. canis* infection, 656
diagnosis of hepatitis C virus, 700
diagnosis of Lyme borreliosis, 731
hantavirus infection, 861
mannanaemia and anti-mannan antibodies in candidosis, 433
Serotyping
group B streptococci, 595
Sexually transmitted diseases
microbiology and management, 793
see also specific organisms
Sheep model
E. coli AE lesions in ligated colon loops, 755
Shiga toxigenic *E. coli*, 332, 405, 548
Signature tagged mutagenesis, 539
Silver sulphadiazine
effects on exoprotein production by *S. aureus*, 50
Skin lesions
secondary bacterial infections, 808
Sorbitol
fermentation by verocytotoxigenic *E. coli*, 713
Spores
B. anthracis, 821
B. cereus, 990
C. perfringens, 990
C. novyi, 971, 985, 990
Sporothrix schenckii
melanin production, 189
Staphylococci
coagulase-negative, 83
determination of methicillin resistance, 83
in microflora of heroin, 1001
S. aureus, adherence properties, 747
S. aureus, fusidic acid- and rifampicin-resistant, 1113
S. aureus, methicillin-resistant (MRSA), 283, 516, 1113

S. aureus, molecular characterisation of EMRSA-15 and EMRSA-16, 516
S. aureus, rapid antimicrobial susceptibility testing, 192
S. aureus, rapid identification of blood cultures, 530
S. aureus, secondary infections in skin lesions, 808
S. aureus, silver sulphadiazine and exoprotein production, 50
S. aureus, subtractive hybridisation studies, 463
S. aureus, in suppurative sialadenitis, 526
S. epidermidis, mixed biofilm with *C. albicans*, 344
S. epidermidis, rapid antimicrobial susceptibility testing, 192
S. saprophyticus, rapid antimicrobial susceptibility testing, 192

Streptococci
antibodies in post-streptococcal glomerulonephritis, 589
β-haemolytic, 791, 808
establishment in respiratory tract of infants, 723
group B, subtractive hybridisation studies, 463
group B, typing of human isolates, 595
IgA1 protease production, 723
invasive infections, 791
nutritionally variant *see Abiotrophia defectiva*
S. defectivus see Abiotrophia defectiva
secondary infections in skin lesions, 808
S. intermedius, *ily* gene as species marker, 178
S. intermedius, PCR identification, 178
S. mutans, bacteriocin-producing clusters, 941
S. mutans in children's dental plaque, 443
S. pneumoniae, α-enolase, 837
S. pneumoniae, antibiotic susceptibility, 907
S. pneumoniae, carriage, 98
S. pneumoniae, in community-acquired pneumonia, 907
S. pneumoniae, community-acquired pneumonia in children, 903
S. pneumoniae, conjugate vaccines, 98
S. pneumoniae, disease (review), 98
S. pneumoniae, in HIV infection, 906
S. pneumoniae, interaction with alveolar macrophages, 905
S. pneumoniae, vaccine, 905
S. sobrinus in children's dental plaque, 443
Strongyloides stercoralis
genital lesions, 805
Sublingual gland infection, 526
Submandibular gland infection, 526
Sudden infant death syndrome (SIDS), 1009
Surveillance
epidemic syphilis, 800
meningococcal serogroup C disease, 717
severe illness in injecting drug users, 971, 978
Syphilis, epidemic, 800

Taenia spp.
infestation in appendix, 90
Taxonomy
gram-positive anaerobic cocci, 949
Tetracycline
resistance of *L. monocytogenes*, 564
susceptibility of *H. pylori*, 705, 786
Thermoactinomyces spp.
improved molecular identification, 1117
Toxins
A. actinomycetemcomitans, 1013
B. anthracis, 821
C. botulinum, 286, 813
C. difficile, 34
C. novyi, 971, 985, 990
C. perfringens, 169, 891, 985, 990
E. coli, 1041
S. aureus, 50
Toxoplasma gondii
model of maternofetal transmission, 871
molecular diagnosis of reactivated encephalitis, 879
Toxoplasmosis, 871
Translocation, bacterial, 687
Trench fever, 915
Treponema spp.
T. denticola, detection by molecular methods, 1090
T. pallidum, epidemic syphilis, 800
T. pallidum, subtractive hybridisation studies, 464
Trichophyton spp.
PCR identification, 117
T. gourvilii, PCR identification, 117
T. mentagrophytes, effect of lactoferrin feeding on host antifungal response, 844
T. rubrum, PCR identification, 117
T. soudanense, PCR identification, 117
Trichosporin asahi
phenotypic changes in environmental isolates, 423
TTGE (temporal temperature gradient gel electrophoresis), 557
TT virus infection, 455
Tuberculosis, 273, 710, 804, 895
Tuberculous epidydimitis, 804
Type IV secretion system
Bartonella spp., 921
Typhoid fever, 173

Urea breath test, 305
Ureaplasma urealyticum
mouse model of colonisation, 866
Urease activity
H. pylori, 231, 958
P. mirabilis, 958
Urinary tract infection
rapid antimicrobial susceptibility testing, 192
uropathogen virulence genes of *E. coli*, 138
Urine
screening test for *C. trachomatis*, 1021

Vaccines
against *B. abortus*, 20, 661
against HSV-1, 350
against *S. pneumoniae*, 98
conjugate, 717, 905
DNA, 350, 661
meningococcal C conjugate, 717
S. pneumoniae, 905
Vascular endothelial growth factor (VEGF)
in infection by *Bartonella* spp., 919
Venereology, 794
Verocytotoxigenic *E. coli* (VTEC), 143, 201, 713
Verruaga peruana, 916
Vibrio cholerae
molecular and phenotypic analysis, 392
PFGE and phenotypic study, 264
Virulence factors
A. actinomycetemcomitans, 1013
A. fumigatus, 1128
Bartonella spp., 915
B. bronchiseptica, 557
B. cepacia, 533, 911
C. albicans, 929
E. coli, 138, 548, 1041
H. pylori, 495, 771, 851, 958
melanins in fungal pathogens, 189
N. meningitidis, 855
P. aeruginosa, 910, 1063
P. alcalifaciens, 682
P. mirabilis, 958
role of comparative genomics, 7
S. aureus, 50, 516, 747
Scedosporium prolificans, 924
S. enterica serotype Typhimurium, 247
Voriconazole
susceptibility of *Candida* spp., 479

Western blotting
plasminogen-binding of *S. pneumoniae* α-enolase, 837

Yeasts
bloodstream infections, 677
media for primary isolation, 221
see also specific organisms
Yersinia spp.
characterisation of *Y. enterocolitica* -like strains, 56
Y. pestis, interaction with erythrocytes, 150

INDEX OF AUTHORS FOR VOLUME 51

ABBOTT S L *see* JANDA *et al.*, 575
ABEL A B *see* LEJBKOWICZ *et al.*, 90
ABO-EL-NAGA S *see* EL-MAHALLAWY *et al.*, 601
ABU-HASAN N *see* ADWAN *et al.*, 332
ACUÑA R *see* FIGUEROA *et al.*, 300
ADAM B, BAILLIE G S, DOUGLAS L J. Mixed species biofilms of *Candida albicans* and *Staphylococcus epidermidis*, 344
ADEGBOLA R *see* OBARO AND ADEGBOLA, 98
ADWAN K, ABU-HASAN N, ESSAWI T, BDIR M. Isolation and characterisation of Shiga toxigenic *Escherichia coli* strains from northern Palestine, 332
AHMED S *see* McGUIGAN *et al.*, 971
AHMED S *see* McLAUCHLIN *et al.*, 990
AKIMOTO S *see* GOTO *et al.*, 178
ALAM K *see* RAHMAN *et al.*, 682
ALAM M *see* RAHMAN *et al.*, 682
ALBERT M J *see* RAHMAN *et al.*, 682
ALCALÁ B, SALCEDO C, ARREAZA L, BERRÓN S, DE LA FUENTE L, VÁZQUEZ J A. The epidemic wave of meningococcal disease in Spain in 1996–1997: probably a consequence of strain displacement, 1102
ALIAGA L, MEDIAVILLA J D, COBO F. A clinical index predicting mortality with *Pseudomonas aeruginosa* bacteraemia, 615
ALI-EL-DIN N H *see* EL-MAHALLAWY *et al.*, 601
ALLAKER R P, YOUNG K A, HARDIE J M, DOMIZIO P, MEADOWS N J. Prevalence of *Helicobacter pylori* at oral and gastrointestinal sites in children: evidence for possible oral-to-oral transmission, 312
ALVES M J *see* LLEDÓ *et al.*, 861
ANSARUZZAMAN M *see* RAHMAN *et al.*, 682
ARAKAKI N, HIGA F, KOIDE M, TATEYAMA N, SAITO A. Induction of apoptosis of human macrophages *in vitro* by *Legionella longbeachae* through activation of the caspase pathway, 159
ARANCIA G *see* FATTORINI *et al.*, 1071
ARIGBABU A O *see* SMITH *et al.*, 851
ARIMITSU H *see* MAHMUT *et al.*, 286, 813
ARREAZA L *see* ALCALÁ *et al.*, 1102
ARVILOMMI H *see* SAARINEN *et al.*, 13
ASHA N J, WILCOX M H. Laboratory diagnosis of *Clostridium perfringens* antibiotic-associated diarrhoea, 891
ASHTON J R *see* McLAUCHLIN *et al.*, 1001
ATKINS T, PRIOR R, MACK K, RUSSELL P, NELSON M, PRIOR J, ELLIS J, OYSTON P C F, DOUGAN G, TITBALL R W. Characterisation of an acapsular mutant of *Burkholderia pseudomallei* identified by signature tagged mutagenesis, 539
ATTIA I *see* EL-MAHALLAWY *et al.*, 601
AUGUSTYNOWICZ E, GZYL A, ŚLUSARCZYK J. Detection of enterotoxigenic *Clostridium perfringens* with a duplex PCR, 169
AURELI P *see* POURSHABAN *et al.*, 564
AYALA S M *see* LUCERO *et al.*, 656
AZEVEDO V *see* LECLERQ *et al.*, 20
AZEVEDO V *see* ROSINHA *et al.*, 661

BAGHIAN A, CHOULJENKO V N, D'AUVERGNE O, NEWMAN M J, BAGHIAN S, KOUSOULAS K G. Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD, 350
BAGHIAN S *see* BAGHIAN *et al.*, 350
BAILLIE G S *see* ADAM *et al.*, 344
BAIRD R *see* LIU *et al.*, 117
BALAKRISHNAN M, SIMMONDS R S, KILIAN M, TAGG J R. Different bacteriocin activities of *Streptococcus mutans* reflect distinct phylogenetic lineages, 941
BALDWIN A *see* MAHENTHIRALINGAM *et al.*, 533
BALMER P, BORROW R, MILLER E. Impact of meningococcal C conjugate vaccine in the UK, 717
BARR J G *see* McILHATTON *et al.*, 468
BARR J G *see* XU *et al.*, 1117
BARRETT A, MAGEE J G, FREEMAN R. An evaluation of the BD ProbeTec ET system for the direct detection of *Mycobacterium tuberculosis* in respiratory samples, 895
BARRETT A *see* FREEMAN *et al.*, 92
BAYERDÖFFER E *see* SMITH *et al.*, 851
BDIR M *see* ADWAN *et al.*, 332
BDOUR S. Hepatitis C virus infection in Jordanian haemodialysis units: serological diagnosis and genotyping, 700
BEECHING N J *see* HART *et al.*, 903
BELLIS M A *see* McLAUCHLIN *et al.*, 1001
BELTRÁN M *see* LLEDÓ *et al.*, 861
BERGH K *see* MOYO *et al.*, 595
BERNASCONI M V *see* GUTACKER *et al.*, 123
BERRÓN S *see* ALCALÁ *et al.*, 1102
BERROTERAN A, PERRONE M, CORRENTI M, CAVAZZA M E, TOMBAZZI C, GONCALVEZ R, LECUNA V. Detection of *Helicobacter pylori* DNA in the oral cavity and gastroduodenal system of a Venezuelan population, 764
BETTELHEIM K A, WHIPP M, DJORDJEVIC S P, RAMACHANDRAN V. First isolation outside Europe of sorbitol-fermenting verocytotoxigenic *Escherichia coli* (VTEC) belonging to O group O157, 713
BETTELHEIM K A *see* GOLDWATER AND BETTELHEIM, 1009
BIDOCHKA M J *see* ROSEHART *et al.*, 1128
BINNS S H *see* SHINA *et al.*, 557
BIRKELUND S *see* FRIIS SVENSTRUP *et al.*, 361
BIRLEY H, DUERDEN B I, HART C A. Sexually transmitted diseases: microbiology and management, 793
BLACK M *see* McGUIGAN *et al.*, 971
BOLTON A J *see* ROBEY *et al.*, 247
BOLTON F J *see* McLAUCHLIN *et al.*, 1001
BONNIN A *see* SENDID *et al.*, 433
BOOS C *see* INCE *et al.*, 899
BORROW R *see* BALMER *et al.*, 717
BOSWELL T C *see* OLVER *et al.*, 221
BOURLET T *see* FLORI *et al.*, 871
BOYANOVA L, KOUMANOVA R, GERGOVA G, POPOVA M, MITOV I, KOVACHEVA Y, DEREJIAN S, KATSAROV N, NIKOLOV R, KRASTEV Z. Prevalence of resistant *Helicobacter pylori* isolates in Bulgarian children, 786
BRAZIER J *see* HILL *et al.*, 949
BRAZIER J S, DUERDEN B I, HALL V, SALMON J E, HOOD J, BRETT M M, McLAUCHLIN J, GEORGE R C. Isolation and identification of *Clostridium* spp. from infections associated with the injection of drugs: experiences of a microbiological investigation team, 985
BRAZIER J S, HALL V, YUSUF E, DUERDEN B I. *Fusobacterium necrophorum* infections in England and Wales, 1990–2000, 269
BRAZIER J S *see* McLAUCHLIN *et al.*, 990
BRETT M M *see* BRAZIER *et al.*, 985
BRETT M M *see* McLAUCHLIN *et al.*, 990
BROOK I. Aerobic and anaerobic microbiology of suppurative sialadenitis, 526
BROOK I. Secondary bacterial infections complicating skin lesions, 808
BROWN N L *see* ROBEY *et al.*, 247
BRYK A *see* KÖNÖNEN *et al.*, 723
BULL T *see* HERMON-TAYLOR AND BULL, 3
BURGESS D S *see* NASH *et al.*, 105
BUSHMICH S L *see* MAGNARELLI *et al.*, 326

CAILLOT D *see* SENDID *et al.*, 433
CALZA L, MANFREDI R, MARINACCI G, FORTUNATO L, CHIODO F. Community-acquired *Pseudomonas aeruginosa* sacro-iliitis in a previously healthy patient, 620
CALZA L *see* MANFREDI *et al.*, 1135
CAMPBELL L A, KUO C-C. *Chlamydia pneumoniae* pathogenesis, 623
CAMUS D *see* SENDID *et al.*, 433
CANT A J *see* HART *et al.*, 903
CAVAZZA M E *see* BERROTERAN *et al.*, 764
CHAE G-T, KIM M-J, KANG T-J, LEE S-B, SHIN H-K, KIM J-P, KO Y-H, KIM S-H, KIM N-H. DNA-PCR and RT-PCR for the 18-kDa gene of *Myocobacterium leprae* to assess the efficacy of multi-drug therapy for leprosy, 417
CHAKRABORTI A *see* SHARMA *et al.*, 399
CHAN B Y-L *see* LAU *et al.*, 635
CHAO L-L *see* SHIH AND CHAO, 318
CHART H, CHEASTY T, WILLSHAW G A. Production of serum antibodies that recognise epitopes located on the R3 region of *Escherichia coli* core lipopolysaccharides by patients infected with strains of enterohaemorrhagic *E. coli*, 1050
CHART H, PERRY N T, CHEASTY T, WRIGHT P A. The kinetics of antibody production to antigens of *Escherichia coli* O157 in a pregnant woman with haemolytic uraemic syndrome, 522
CHEASTY T *see* CHART *et al.*, 522, 1050
CHEETHAM P *see* OLVER *et al.*, 221
CHIODO F *see* CALZA *et al.*, 620

CHIODO F *see* MANFREDI *et al.*, 1135
CHOULJENKO V N *see* BAGHIAN *et al.*, 350
CHRISTIANSEN G *see* FRIIS SVENSTRUP *et al.*, 361
CINQUE P *see* CONTINI *et al.*, 879
CLIFTON-HADLEY F A *see* WALES *et al.*, 755
COBO F *see* ALIAGA *et al.*, 615
COENYE T *see* VERMIS *et al.*, 937
COHEN H I *see* LEJBKOWICZ *et al.*, 90
COKER A O *see* SMITH *et al.*, 851
COKER C *see* McGEE *et al.*, 958
COLODNER R *see* MARRS *et al.*, 138
COLOE S *see* LIU *et al.*, 117
COLOMBO A P *see* SIQUEIRA *et al.*, 1090
CONTINI C, CULTRERA R, SERACENI S, SEGALA D, ROMANI R, FAINARDI E, CINQUE P, LAZZARIN A, DELIA S. The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated *Toxoplasma gondii* encephalitis in patients with AIDS, 879
COOKSON A L, HAYES C M, PEARSON G R, ROE J M, WALES A D, WOODWARD M J. Isolation from a sheep of an attaching and effacing *Escherichia coli* O115:H$^-$ with a novel combination of virulence factors, 1041
COOKSON A L, WALES A D, ROE J M, HAYES C M, PEARSON G R, WOODWARD M J. Variation in the persistence of *Escherichia coli* O157:H7 in experimentally inoculated 6-week-old conventional lambs, 1032
COOKSON A L *see* WALES *et al.*, 755
CORRENTI M *see* BERROTERAN *et al.*, 764
CRETI R *see* FATTORINI *et al.*, 1071
CULTRERA R *see* CONTINI *et al.*, 879
CURRAN M D *see* McILHATTON *et al.*, 468
CURRIE C *see* HOEY *et al.*, 143

DANCER S J, McNAIR D, FINN P, KOLSTO A-B. *Bacillus cereus* cellulitis from contaminated heroin, 278
DARDIK R *see* SHENKMAN *et al.*, 747
DAS B *see* MATHUR *et al.*, 791
DAS B C *see* KAILASH *et al.*, 606
D'AUVERGNE O *see* BAGHIAN *et al.*, 350
DAVIES C E *see* HILL *et al.*, 949
DAWSON S *see* SHINA *et al.*, 557
DE CAROLIS E *see* PELLETIER *et al.*, 479
DE LA FUENTE L *see* ALCALÁ *et al.*, 1102
DELIA S *see* CONTINI *et al.*, 879
DE MAN R A *see* NIESTERS *et al.*, 695
DEOL K *see* TIWARI *et al.*, 503
DEREJIAN S *see* BOYANOVA *et al.*, 786
DE UZEDA M *see* SIQUEIRA *et al.*, 1090
DEVDARIANI Z L *see* FEODOROVA AND DEVDARIANI, 150
DHAWAN B *see* MATHUR *et al.*, 791
DIBB-FULLER M P *see* WALES *et al.*, 755
DJORDJEVIC S P *see* BETTELHEIM *et al.*, 713
DJURETIC T *see* JONES *et al.*, 978
DLUHOLUCKY S *see* KRCMERY *et al.*, 110
DÓCZI I, DÓSA E, HAJDÚ E, NAGY E. Aetiology and antifungal susceptibility of yeast bloodstream infections in a Hungarian university hospital between 1996 and 2000, 677
DOI T *see* OKADA *et al.*, 443
DOLMANS W M V *see* GASEM *et al.*, 173
DOMIZIO P *see* ALLAKER *et al.*, 312
DORRELL N *see* ZHANG *et al.*, 495
DÓSA E *see* DÓCZI *et al.*, 677
DÓSA E *see* KNAUSZ *et al.*, 187
DOUGAN G *see* ATKINS *et al.*, 539
DOUGLAS L J *see* ADAM *et al.*, 344
DRASBEK M *see* FRIIS SVENSTRUP *et al.*, 361
DUERDEN B I. A new home for the *Journal*, 1
DUERDEN B I *see* BIRLEY *et al.*, 793
DUERDEN B I *see* BRAZIER *et al.*, 269, 985
DUERDEN B I *see* HART *et al.*, 903
DUNN J *see* FREEMAN *et al.*, 92
DWIVEDI S N *see* MATHUR *et al.*, 791

EBISU S *see* YAMADA *et al.*, 1080
EDWARDS-JONES V, FOSTER H A. Effects of silver sulphadiazine on the production of exoproteins by *Staphylococcus aureus*, 50
EISHI Y *see* KOBAYASHI *et al.*, 305
EKMAN P *see* SAARINEN *et al.*, 13
ELBORN J S *see* XU *et al.*, 1117
ELLIS J *see* ATKINS *et al.*, 539
ELLIS J F *see* JONES *et al.*, 1055
ELLIS M. Amphotericin B and invasive aspergillosis – how do the data guide us?, 95
ELLIS M, WATSON R, McNABB A, LUKIC M L, NORK M. Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery, 70
EL-MAHALLAWY H A, ATTIA I, ALI-EL-DIN N H, SALEM A E, ABO-EL-NAGA S. A prospective study on fungal infection in children with cancer, 601
ELSE R W *see* HOEY *et al.*, 143
ENDO T *see* TAKAHASHI *et al.*, 510, 611
ENGELICH G, WHITE M, HARTSHORN K L. Role of respiratory burst in co-operative reduction in neutrophil survival by influenza A virus and *Escherichia coli*, 484
ESCOBAR G I *see* LUCERO *et al.*, 656
ESSAWI T *see* ADWAN *et al.*, 332
EVANS J *see* XU *et al.*, 1117
EVANS J T *see* WHITING *et al.*, 837
EZAKI T *see* GOTO *et al.*, 178

FAINARDI E *see* CONTINI *et al.*, 879
FAN Y *see* FATTORINI *et al.*, 1071
FARTHING M J G *see* ZHANG *et al.*, 495
FATTORINI L, CRETI R, NISINI R, PIETROBONO R, FAN Y, STRINGARO A, ARANCIA G, SERLUPI-CRESCENZI O, IONA E, OREFICI G. Recombinant GroES in combination with CpG oligodeoxynucleotides protects mice against *Mycobacterium avium* infection, 1071
FAÚNDEZ G *see* FIGUEROA *et al.*, 300
FELIPE I *see* PANAGIO *et al.*, 929
FEODOROVA V A, DEVDARIANI Z L. The interaction of *Yersinia pestis* with erythrocytes, 150
FERRINI A M *see* POURSHABAN *et al.*, 564
FIGUEROA G, TRONCOSO M, TOLEDO M S, FAÚNDEZ G, ACUÑA R. Prevalence of serum antibodies to *Helicobacter pylori* VacA and CagA and gastric diseases in Chile, 300
FIKRIG E *see* MAGNARELLI *et al.*, 326, 649
FILKA J *see* KRCMERY *et al.*, 110
FINN P *see* DANCER *et al.*, 278
FLORI P, HAFID J, BOURLET T, RABERIN H, GENIN C, TRAN MANH SUNG R. Experimental model of congenital toxoplasmosis in guinea-pigs: use of quantitative and qualitative PCR for the study of maternofetal transmission, 871
FORSBLOM B, SARKIALA-KESSEL E, KANERVO A, VÄISÄNEN M-L, HELANDER M, JOUSIMIES-SOMER H. Characterisation of aerobic gram-negative bacteria from subgingival sites of dogs – potential bite wound pathogens, 207
FORTUNATO L *see* CALZA *et al.*, 620
FOSTER H A *see* EDWARDS-JONES AND FOSTER, 50
FOX A J *see* TROTTER *et al.*, 855
FOXMAN B *see* MARRS *et al.*, 138
FREEMAN R, DUNN J, MAGEE J, BARRETT A. The enhancement of isolation of mycobacteria from a rapid liquid culture system by broth culture supernate of *Micrococcus luteus*, 92
FREEMAN R *see* BARRETT *et al.*, 895
FRIEDLANDER A *see* WELKOS *et al.*, 821
FRIES E *see* NIESTERS *et al.*, 695
FRIIS SVENSTRUP H, NIELSEN P K, DRASBEK M, BIRKELUND S, CHRISTIANSEN G. Adhesion and inhibition assay of *Mycoplasma genitalium* and *M. pneumoniae* by immunofluorescence microscopy, 361
FUJINAGA Y *see* MAHMUT *et al.*, 286, 813
FUJIOKA Y *see* TAGUCHI *et al.*, 336
FUJIWARA O *see* NAGANO *et al.*, 405
FUKADA M *see* OSAKI *et al.*, 295
FUNG A M-Y *see* LAU *et al.*, 635
FURR P M *see* TAYLOR-ROBINSON AND FURR, 866
FYFE L *see* SMITH-PALMER *et al.*, 567

GALLY D L *see* HOEY *et al.*, 143
GANGULY N K *see* SHARMA *et al.*, 399
GARCÍA A *see* SALGADO *et al.*, 771
GARCÍA P, LEVICAN J, QUIROGA T, MONTIEL F, PALAVECINO E. Direct identification of *Staphylococcus aureus* from positive blood culture specimens with a rapid test, 530
GASEM M H, SMITS H L, GORIS M G A, DOLMANS W M V. Evaluation of a simple and rapid dipstick assay for the diagnosis of typhoid fever in Indonesia, 173
GASKELL R M *see* SHINA *et al.*, 557
GAUTHIER C, ST-PIERRE Y, VILLEMUR R. Rapid antimicrobial susceptibility testing of urinary tract isolates and samples by flow cytometry, 192
GAZIRI L C J *see* PANAGIO *et al.*, 929
GEGÚNDEZ M I *see* LLEDÓ *et al.*, 861
GENIN C *see* FLORI *et al.*, 871
GEORGE R C *see* BRAZIER *et al.*, 985

GEORGE R C *see* JONES *et al.*, 978
GEORGE R C *see* McLAUCHLIN *et al.*, 990
GERGOVA G *see* BOYANOVA *et al.*, 786
GIBSON S V *see* McGEE *et al.*, 958
GILL O N *see* JONES *et al.*, 978
GILLE J *see* INCE *et al.*, 899
GILLESPIE S H *see* WHITING *et al.*, 837
GOLDBERG D *see* McGUIGAN *et al.*, 971
GOLDWATER P N, BETTELHEIM K A. Curliated *Escherichia coli*, soluble curlin and the sudden death syndrome (SIDS), 1009
GOMEZ B L *see* HAMILTON AND GOMEZ, 189
GONCALVEZ R *see* BERROTERAN *et al.*, 764
GONZÁLEZ C *see* SALGADO *et al.*, 771
GOPALKRISHNA V *see* KAILASH *et al.*, 606
GORDON S B *see* HART *et al.*, 903
GORIS M G A *see* GASEM *et al.*, 173
GOTO M *see* TAKAHASHI *et al.*, 611
GOTO T, NAGAMUNE H, MIYAZAKI A, KAWAMURA Y, OHNISHI O, HATTORI K, OHKURA K, MIYAMOTO K, AKIMOTO S, EZAKI T, HIROTA K, MIYAKE Y, MAEDA T, KOURAI H. Rapid identification of *Streptococcus intermedius* by PCR with the *ily* gene as a species marker gene, 178
GRANFORS K *see* SAARINEN *et al.*, 13
GRAY S J *see* TROTTER *et al.*, 855
GREUB G, RAOULT D. *Bartonella* : new explanations for old diseases, 915
GREWAL J S *see* TIWARI *et al.*, 503
GRIFFIN K F *see* JONES *et al.*, 1055
GRIMONT F *see* POURSHAFIE *et al.*, 392
GRIMONT P A D *see* POURSHAFIE *et al.*, 392
GRUER L *see* McGUIGAN *et al.*, 971
GUARRO J *see* ORTONEDA *et al.*, 924
GUTACKER M, VALSANGIACOMO C, BERNASCONI M V, PIFFARETTI J-C. *recA* and *glnA* sequences separate the *Bacteroides fragilis* population into two genetic divisions associated with the antibiotic resistance genotypes *cepA* and *cfiA*, 123
GZYL A *see* AUGUSTYNOWICZ *et al.*, 169

HAFID J *see* FLORI *et al.*, 871
HAJDÚ E *see* DÓCZI *et al.*, 677
HALL V *see* BRAZIER *et al.*, 269, 985
HALL V *see* HILL *et al.*, 949
HAMILTON AJ, GOMEZ B L. Melanins in fungal pathogens, 189
HANZEN J *see* KRCMERY *et al.*, 110
HARDIE J M *see* ALLAKER *et al.*, 312
HARMS J S *see* LECLERQ *et al.*, 20
HARRO J M *see* McGEE *et al.*, 958
HART C A, BEECHING N J, DUERDEN B I (editors), CANT A J, GORDON S B, READ R C, WINSTANLEY C. Respiratory infections. 903
HART C A *see* BIRLEY *et al.*, 793
HART C A *see* RAINBOW *et al.*, 374
HART C A *see* SHINA *et al.*, 557
HARTAS J *see* SRIPRAKASH *et al.*, 589
HARTSHORN K L *see* ENGELICH *et al.*, 484
HATTORI K *see* GOTO *et al.*, 178
HAYASAWA H *see* SHIN *et al.*, 231
HAYASHI F *see* OKADA *et al.*, 443
HAYASHI H *see* MAEGAWA *et al.*, 34
HAYES C M *see* COOKSON *et al.*, 1032, 1041
HE Q *see* SAARINEN *et al.*, 13
HEDAU S *see* KAILASH *et al.*, 606
HEIFETS L. Susceptibility testing of *Mycobacterium tuberculosis* to pyrazinamide, 11
HEIKKILÄ T, SEPPÄLÄ I, SAXEN H, PANELIUS J, PELTOMAA M, HUPPERTZ H-I, LAHDENNE P. Cloning of the gene encoding the decorin-binding protein B (DbpB) in *Borrelia burgdorferi sensu lato* and characterisation of the antibody responses to DbpB in Lyme borreliosis, 641
HEIKKILÄ T *see* PANELIUS *et al.*, 731
HELANDER M *see* FORSBLOM *et al.*, 207
HENDERSON B, WILSON M, SHARP L, WARD JM. *Actinobacillus actinomycetemcomitans*, 1013
HENRICHFREISE B *see* STOCK *et al.*, 56
HENWOOD C J *see* SPENCE *et al.*, 1107
HERMINAJENG E *see* SOSROSENO AND HERMINAJENG, 581
HERMON-TAYLOR J, BULL T. Crohn's disease caused by *Mycobacterium avium* subspecies *paratuberculosis* : a public health tragedy whose resolution is long overdue, 3
HIGA F *see* ARAKAKI *et al.*, 159
HILL K E, DAVIES C E, WILSON M J, STEPHENS P, LEWIS M A O, HALL V, BRAZIER J, THOMAS D W. Heterogeneity within the gram-positive anaerobic cocci demonstrated by analysis of 16S–23S intergenic ribosomal RNA polymorphisms, 949
HIRAMATSU K *see* KARASHIMA *et al.*, 423
HIRAMATSU R *see* MATSUMOTO *et al.*, 264
HIRANO H *see* OSAKI *et al.*, 295
HIROSE M *see* KUROSAWA *et al.*, 385
HIROTA K *see* GOTO *et al.*, 178
HIRST R *see* MAHMUT *et al.*, 813
HO Y-H *see* CHAE *et al.*, 417
HOEY D E E, CURRIE C, ELSE R W, NUTIKKA A, LINGWOOD C A, GALLY D L, SMITH D G E. Expression of receptors for verotoxin 1 from *Escherichia coli* O157 on bovine intestinal epithelium, 143
HOOD J *see* BRAZIER *et al.*, 985
HOOD J *see* McGUIGAN *et al.*, 971
HOOD J *see* McLAUCHLIN *et al.*, 990
HOPKINS M J, MACFARLANE G T. Changes in predominant bacterial populations in human faeces with age and with *Clostridium difficile* infection, 448
HUA S C *see* SUGAWARA *et al.*, 131
HUGHES L *see* MAHMUT *et al.*, 286, 813
HUMPHREYS H. Control of methicillin-resistant *Staphylococcus aureus* in hospitals. An impossible dream?, 283
HUPPERTZ H-I *see* HEIKKILÄ *et al.*, 641
HUTTOVA M *see* KRCMERY *et al.*, 110

IJDO J W *see* MAGNARELLI *et al.*, 326
IKEDA M *see* SAARINEN *et al.*, 13
IKI K *see* SUGIYAMA *et al.*, 27
IMOTO I *see* SHIN *et al.*, 231
INCE A, TIEMER B, GILLE J, BOOS C, RUSSLIES M. Total knee arthroplasty infection due to *Abiotrophia defectiva*, 899
INOUE K *see* MAHMUT *et al.*, 286, 813
IONA E *see* FATTORINI *et al.*, 1071
ISHIGE I *see* KOBAYASHI *et al.*, 305
IWAKURA Y *see* SHINOZAWA *et al.*, 225
IWAMOTO A *see* TAKAHASHI *et al.*, 510, 611
IWATA M *see* KOGA *et al.*, 238

JAMES D *see* SPENCE *et al.*, 1107
JANDA J M, ABBOTT S L, KHASHE S, PROBERT W. Phenotypic and genotypic properties of the genus *Hafnia*, 575
JANTUNEN M E *see* MARRS *et al.*, 138
JONES J A, SALMON J E, DJURETIC T, NICHOLS G, GEORGE R C, GILL O N. An outbreak of serious illness and death among injecting drug users in England during 2000, 978
JONES S M, ELLIS J F, RUSSELL P, GRIFFIN K F, OYSTON P C F. Passive protection against *Burkholderia pseudomallei* infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins, 1055
JOUSIMIES-SOMER H *see* FORSBLOM *et al.*, 207
JOUSIMIES-SOMER H *see* KÖNÖNEN *et al.*, 723

KACZMARSKI E B *see* TROTTER *et al.*, 855
KAILASH U, HEDAU S, GOPALKRISHNA V, KATIYAR S, DAS B C. A simple 'paper smear' method for dry collection, transport and storage of cervical cytological specimens for rapid screening of HPV infection by PCR, 606
KAMEL A G M *see* NORAZAH *et al.*, 1113
KAMIYA S *see* OSAKI *et al.*, 295
KAMIYA S *see* TAGUCHI *et al.*, 336
KANERVO A *see* FORSBLOM *et al.*, 207
KANG T-J *see* CHAE *et al.*, 417
KAPIL A *see* MATHUR *et al.*, 791
KARASAWA T *see* MAEGAWA *et al.*, 34
KARASAWA T *see* MAHMUT *et al.*, 813
KARASHIMA R, YAMAKAMI Y, YAMAGATA E, TOKIMATSU I, HIRAMATSU K, NASU M. Increased release of glucuronoxylomannan antigen and induced phenotypic changes in *Trichosporon asahii* by repeated passage in mice, 423
KATIYAR S *see* KAILASH *et al.*, 606
KATO H *see* MAEGAWA *et al.*, 34
KATSAROV N *see* BOYANOVA *et al.*, 786
KATSUTA M *see* KOGA *et al.*, 777
KAUR R *see* SHARMA *et al.*, 399
KAWAGUCHI F *see* SALGADO *et al.*, 771
KAWAKAMI H *see* OSAKI *et al.*, 295
KAWAMOTO H *see* MISAWA *et al.*, 86
KAWAMURA Y *see* GOTO *et al.*, 178
KAWASHIMA K *see* MISAWA *et al.*, 86
KEATING C *see* McILHATTON *et al.*, 468
KHASHE S *see* JANDA *et al.*, 575
KIKUCHI I *see* KOGA *et al.*, 238, 777
KILIAN M *see* BALAKRISHNAN *et al.*, 941
KILIAN M *see* KÖNÖNEN *et al.*, 723
KILPI T *see* KÖNÖNEN *et al.*, 723

KIM J-P *see* CHAE *et al.*, 417
KIM M-J *see* CHAE *et al.*, 417
KIM N-H *see* CHAE *et al.*, 417
KIM S-H *see* CHAE *et al.*, 417
KIMURA K *see* TAKAHASHI *et al.*, 510
KIRSCH C *see* SMITH *et al.*, 851
KITAMURA Y *see* TAKAHASHI *et al.*, 510
KNAUSZ M, NIEDERLAND T, DÓSA E, ROZGONYI F. Meningo-Pencephalitis in a neonate caused by maternal *Mycoplasma hominis* treated successfully with chloramphenicol, 187
KOBAYASHI D, EISHI Y, OHKUSA T, ISHIGE I, SUZUKI T, MINAMI J, YAMADA T, TAKIZAWA T, KOIKE M. Gastric mucosal density of *Helicobacter pylori* estimated by real-time PCR compared with results of urea breath test and histological grading, 305
KOGA T, SHIMADA Y, SATO K, TAKAHASHI K, KIKUCHI I, MIURA T, TAKENOUCHI T, NARITA T, IWATA M. Experimental *Helicobacter pylori* gastric infection in miniature pigs, 238
KOGA T, TAKAHASHI K, SATO K, KIKUCHI I, OKAZAKI Y, MIURA T, KATSUTA M, NARITA T. The effect of colonisation by *Helicobacter pylori* in *Praomys* (Mastomys) *natalensis* on the incidence of carcinoids, 777
KOH Y T *see* NORAZAH *et al.*, 1113
KOHESTANI S *see* POURSHAFIE *et al.*, 392
KOIDE M *see* ARAKAKI *et al.*, 159
KOIKE M *see* KOBAYASHI *et al.*, 305
KOLSTO A-B *see* DANCER *et al.*, 278
KOMATSU A *see* TAGUCHI *et al.*, 336
KONDO F *see* MISAWA *et al.*, 86
KÖNIG W *see* WOLLE *et al.*, 705
KÖNÖNEN E, JOUSIMIES-SOMER H, BRYK A, KILPI T, KILIAN M. Establishment of streptococci in the upper respiratory tract: longitudinal changes in the mouth and nasopharynx up to 2 years of age, 723
KOREN P *see* KRCMERY *et al.*, 110
KORTING H C *see* SCHALLER *et al.*, 672
KOUMANOVA R *see* BOYANOVA *et al.*, 786
KOURAI H *see* GOTO *et al.*, 178
KOUSOULAS K G *see* BAGHIAN *et al.*, 350
KOVACHEVA Y *see* BOYANOVA *et al.*, 786
KOZAI K *see* OKADA *et al.*, 443
KRALINSKY K *see* KRCMERY *et al.*, 110
KRASTEV Z *see* BOYANOVA *et al.*, 786
KRCMERY V, LAHO L, HUTTOVA M, ONDRUSOVA A, KRALINSKY K, PEVALOVA L, DLUHOLUCKY S, PISARČÍKOVA M, HANZEN J, FILKA J, SEJNOVÁ D, LIŠKOVA A, PURGELOVÁ A, SZOVENYOVÁ Z, KOREN P. Aetiology, antifungal susceptibility, risk factors and outcome in 201 fungaemic children: data from a 12-year prospective national study from Slovakia, 110
KUMADA H *see* NAGANO *et al.*, 405
KUMAR P, PAI K, PANDEY H P, SUNDAR S. NADH-oxidase, NADPH-oxidase and myeloperoxidase activity of visceral leishmaniasis patients, 832
KUO C-C *see* CAMPBELL AND KUO, 623
KUROSAWA A, MIWA H, HIROSE M, TSUNE I, NAGAHARA A, SATO N. Inhibition of cell proliferation and induction of apoptosis by *Helicobacter pylori* through increased phosphorylated p53, p21 and Bax expression in endothelial cells, 385
KUWAHARA T *see* NARIOKA *et al.*, 687

LAHDENNE P *see* HEIKKILÄ *et al.*, 641
LAHDENNE P *see* PANELIUS *et al.*, 731
LAHO L *see* KRCMERY *et al.*, 110
LARAGIONE R M *see* WALES *et al.*, 755
LAU S K-P, WOO P C-Y, CHAN B Y-L, FUNG A M-Y, QUE T-L, YUEN K-Y. *Haemophilus segnis* polymicrobial and monomicrobial bacteraemia identified by 16S ribosomal RNA gene sequencing, 635
LAWRENZ M *see* MAGNARELLI *et al.*, 649
LAZZARIN A *see* CONTINI *et al.*, 879
LECLERQ S, HARMS J S, ROSINHA G M S, AZEVEDO V, OLIVEIRA S C. Induction of a Th1-type of immune response but not protective immunity by intramuscular DNA immunisation with *Brucella abortus GroEL* heat-shock gene, 20
LECUNA V *see* BERROTERAN *et al.*, 764
LEE M-A *see* LIU *et al.*, 76
LEE S-B *see* CHAE *et al.*, 417
LEJBKOWICZ F, ABEL A B, TSILMAN B, COHEN H I. *Taenia* infestation in the appendix: a report of two cases, 90
LENNON A *see* RIGGIO AND LENNON, 1097
LEODOLTER A *see* WOLLE *et al.*, 705
LEUNG K-W *see* WOO *et al.*, 740
LEVICAN J *see* GARCÍA *et al.*, 530
LEVY S A *see* MAGNARELLI *et al.*, 326
LEWIS M A O *see* HILL *et al.*, 949
LILLEY G *see* LIU *et al.*, 117
LIM V K E *see* NORAZAH *et al.*, 1113
LINDSAY J A *see* MOORE AND LINDSAY, 516
LINGWOOD C A *see* HOEY *et al.*, 143
LIŠKOVA A *see* KRCMERY *et al.*, 110
LITTLE S *see* WELKOS *et al.*, 821
LIU D, PEARCE L, LILLEY G, COLOE S, BAIRD R, PEDERSEN J. PCR identification of dermatophyte fungi *Trichophyton rubrum, T. soudanense* and *T. gourvilii*, 117
LIU Y, WANG D, YAP E H, YAP E P H, LEE M-A. Identification of a novel repetitive DNA element and its use as a molecular marker for strain typing and discrimination of ara$^-$ from ara$^+$ *Burkholderia pseudomallei* isolates, 76
LIVERMORE D M *see* SPENCE *et al.*, 1107
LLEDÓ L, GEGÚNDEZ M I, SAZ J V, ALVES M J, BELTRÁN M. Serological study of hantavirus in man in the Autonomous Community of Madrid, Spain, 861
LODGE J M *see* ROBEY *et al.*, 247
LOPEZ G *see* LUCERO *et al.*, 656
LORANGER L *see* PELLETIER *et al.*, 479
LUCERO N E, ESCOBAR G I, AYALA S M, LOPEZ G. Sensitivity and specificity of an indirect enzyme-linked immunoassay for the diagnosis of *Brucella canis* infection in dogs, 656
LUKIC M L *see* ELLIS *et al.*, 70

MACFARLANE G T *see* HOPKINS AND MACFARLANE, 448
McCRACKEN C M *see* SHINA *et al.*, 557
McGEE D J, COKER C, TESTERMAN T L, HARRO J M, GIBSON S V, MOBLEY H L T. The *Helicobacter pylori flbA* flagellar biosynthesis and regulatory gene is required for motility and virulence and modulates urease of *H. pylori* and *Proteus mirabilis*, 958
McGUIGAN C C, PENRICE G M, GRUER L, AHMED S, GOLDBERG D, BLACK M, SALMON J E, HOOD J. Lethal outbreak of infection with *Clostridium novyi* type A and other spore-forming organisms in Scottish injecting drug users, 971
McILHATTON B P, KEATING C, CURRAN M D, McMULLIN M-F, BARR J G, MADRIGAL J A, MIDDLETON D. Identification of medically important pathogenic fungi by reference strand-mediated conformational analysis (RSCA), 468
MACK K *see* ATKINS *et al.*, 539
McLAUCHLIN J, MITHANI V, BOLTON F J, NICHOLS G L, BELLIS M A, SYED Q, THOMSON R P M, ASHTON J R. An investigation into the microflora of heroin, 1001
McLAUCHLIN J, SALMON J E, AHMED S, BRAZIER J S, BRETT M M, GEORGE R C, HOOD J. Amplified fragment length polymorphism (AFLP) analysis of *Clostridium novyi, C. perfringens* and *Bacillus cereus* isolated from injecting drug users during 2000, 990
McLAUCHLIN J *see* BRAZIER *et al.*, 985
McMULLIN M-F *see* McILHATTON *et al.*, 468
McNABB A *see* ELLIS *et al.*, 70
McNAIR D *see* DANCER *et al.*, 278
MADRIGAL J A *see* McILHATTON *et al.*, 468
MAEDA T *see* GOTO *et al.*, 178
MAEGAWA T, KARASAWA T, OHTA K, WANG X, KATO H, HAYASHI H, NAKAMURA S. Linkage between toxin production and purine biosynthesis in *Clostridium difficile*, 34
MAELAND J A *see* MOYO *et al.*, 595
MAGEE J *see* FREEMAN *et al.*, 92
MAGEE J G *see* BARRETT *et al.*, 895
MAGNARELLI L A, IJDO J W, SHERMAN B A, BUSHMICH S L, LEVY S A, FIKRIG E. Antibodies to granulocytic ehrlichiae in cattle from Connecticut, 326
MAGNARELLI L A, LAWRENZ M, NORRIS S J, FIKRIG E. Comparative reactivity of human sera to recombinant VlsE and other *Borrelia burgdorferi* antigens in class-specific enzyme-linked immunosorbent assays for Lyme borreliosis, 649
MAHENTHIRALINGAM E, BALDWIN A, VANDAMME P. *Burkholderia cepacia* complex infection in patients with cystic fibrosis, 533
MAHENTHIRALINGAM E *see* VERMIS *et al.*, 937
MAHMUT N, INOUE K, FUJINAGA Y, ARIMITSU H, SAKAGUCHI Y, HUGHES L, HIRST R, MURPHY T, TSUJI T, WATANABE T, OHYAMA T, KARASAWA T, NAKAMURA S, YOKOTA K, OGUMA K. Mucosal immunisation with *Clostridium botulinum* type C 16 S toxoid and its non-toxic component, 813
MAHMUT N, INOUE K, FUJINAGA Y, HUGHES L, ARIMITSU H, SAKAGUCHI Y, OHTSUKA A, MURAKAMI T, YOKOTA K, OGUMA K. Characterisation of monoclonal antibodies against haemagglutinin associated with *Clostridium botulinum* type C neurotoxin, 286
MAILHAMMER R *see* SCHALLER *et al.*, 672
MALFERTHEINER P *see* WOLLE *et al.*, 705
MALLARD R *see* TROTTER *et al.*, 855
MANFREDI R, CALZA L, CHIODO F. Dual *Candida albicans* and *Cryptococcus neoformans* fungaemia in an AIDS presenter: a

unique disease association in the highly active antiretroviral therapy (HAART) era, 1135
MANFREDI R *see* CALZA *et al.*, 620
MANNING S D *see* MARRS *et al.*, 138
MANNONI V *see* POURSHABAN *et al.*, 564
MARCOTTE H *see* PELLETIER *et al.*, 479
MARDH P-A *see* WATSON *et al.*, 1021
MARINACCI G *see* CALZA *et al.*, 620
MARRS C F, ZHANG L, TALLMAN P, MANNING S D, SOMSEL P, RAZ P, COLODNER R, JANTUNEN M E, SIITONEN A, SAXEN H, FOXMAN B. Variations in 10 putative uropathogen virulence genes among urinary, faecal and peri-urethral *Escherichia coli*, 138
MARTÍN C *see* RUIZ GARCIA *et al.*, 273
MARTIN G D *see* ROBEY *et al.*, 247
MATHUR P, KAPIL A, DAS B, DHAWAN B, DWIVEDI S N. Invasive β-haemolytic streptococcal infections in a tertiary care hospital in northern India, 791
MATSUI H *see* MATSUMOTO *et al.*, 264
MATSUMOTO M, SUZUKI M, HIRAMATSU R, YAMAZAKI M, MATSUI H, SAKAE K, SUZUKI Y, MIYAZAKI Y. Epidemiological investigation of a fatal case of cholera in Japan by phenotypic techniques and pulsed-field gel electrophoresis, 264
MATSUMOTO T *see* SHINOZAWA *et al.*, 225
MATSUO T *see* YAMADA *et al.*, 1080
MATSUSHITA K *see* SUGIYAMA *et al.*, 27
MAYAYO E *see* ORTONEDA *et al.*, 924
MEADOWS N J *see* ALLAKER *et al.*, 312
MEDIAVILLA J D *see* ALIAGA *et al.*, 615
MENDELSON I *see* WELKOS *et al.*, 821
MIDDLETON D *see* McILHATTON *et al.*, 468
MIEHLKE S *see* SMITH *et al.*, 851
MILLAR B C *see* XU *et al.*, 1117
MILLER E *see* BALMER *et al.*, 717
MINAMI J *see* KOBAYASHI *et al.*, 305
MISAWA N, KAWASHIMA K, KAWAMOTO H, KONDO F. Development of a combined filtration-enrichment culture followed by a one-step duplex PCR technique for the rapid detection of *Campylobacter jejuni* and *C. coli* in human faecal samples, 86
MITHANI V *see* McLAUCHLIN *et al.*, 1001
MITOV I *see* BOYANOVA *et al.*, 786
MIURA K *see* OKADA *et al.*, 443
MIURA T *see* KOGA *et al.*, 238, 777
MIWA H *see* KUROSAWA *et al.*, 385
MIYAKE Y *see* GOTO *et al.*, 178
MIYAMOTO K *see* GOTO *et al.*, 178
MIYAZAKE A *see* GOTO *et al.*, 178
MIYAZAKI Y *see* MATSUMOTO *et al.*, 264
MOBLEY H L T *see* McGEE *et al.*, 958
MONIRA S *see* RAHMAN *et al.*, 682
MONTIEL F *see* GARCÍA *et al.*, 530
MOORE J E *see* XU *et al.*, 1117
MOORE P C L, LINDSAY J A. Molecular characterisation of the dominant UK methicillin-resistant *Staphylococcus aureus* strains, EMRSA-15 and EMRSA-16, 516
MORGAN E *see* ROBEY *et al.*, 247
MORIMOTO Y *see* NAGANO *et al.*, 405
MORISHITA Y *see* SHIN *et al.*, 201
MOYO S R, MAELAND J A, BERGH K. Typing of human isolates of *Streptococcus agalactiae* (group B streptococcus, GBS) strains from Zimbabwe, 595
MURAKAMI T *see* MAHMUT *et al.*, 286
MURPHY T *see* MAHMUT *et al.*, 813
MYIOSHI A *see* ROSINHA *et al.*, 661

NAGAHARA A *see* KUROSAWA *et al.*, 385
NAGAMUNE H *see* GOTO *et al.*, 178
NAGANO H, OKUI T, FUJIWARA O, UCHIYAMA Y, TAMATE N, KUMADA H, MORIMOTO Y, YANO S. Clonal structure of Shiga toxin (Stx)-producing and β-D-glucuronidase-positive *Escherichia coli* O157:H7 strains isolated from outbreaks and sporadic cases in Hokkaido, Japan, 405
NAGY E *see* DÓCZI *et al.*, 677
NAHAR S *see* RAHMAN *et al.*, 682
NAKAE H *see* YAMADA *et al.*, 1080
NAKAMURA R *see* SUGIYAMA *et al.*, 27
NAKAMURA S *see* MAEGAWA *et al.*, 34
NAKAMURA S *see* MAHMUT *et al.*, 813
NAKAMURA T *see* TAKAHASHI *et al.*, 510, 611
NAKAYAMA H *see* NARIOKA *et al.*, 687
NARIOKA J, NISHI M, OGATA Y, KUWAHARA T, NAKAYAMA H, TASHIRO S, OHNISHI Y. Promotion of bacterial translocation by major liver resection in obstructive jaundice in rats colonised predominantly with indigenous *Escherichia coli*, 687
NARITA T *see* KOGA *et al.*, 238, 777
NASH J D, BURGESS D S, TALBERT R L. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against *Candida albicans*, 105
NASU M *see* KARASHIMA *et al.*, 423
NAVARRO J F *see* RUIZ GARCIA *et al.*, 273
NELIS H J *see* VERMIS *et al.*, 937
NELSON M *see* ATKINS *et al.*, 539
NEWMAN M J *see* BAGHIAN *et al.*, 350
NG P P *see* NORAZAH *et al.*, 1113
NICHOLS G *see* JONES *et al.*, 978
NICHOLS G L *see* McLAUCHLIN *et al.*, 1001
NIEDERLAND T *see* KNAUSZ *et al.*, 187
NIELSEN P K *see* FRIIS SVENSTRUP *et al.*, 361
NIESTERS H G M, DE MAN R A, PAS S D, FRIES E, OSTERHAUS A D M E. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy, 695
NIKOLOV R *see* BOYANOVA *et al.*, 786
NISHI M *see* NARIOKA *et al.*, 687
NISINI R *see* FATTORINI *et al.*, 1071
NORAZAH A, LIM V K E, KOH Y T, ROHANI M Y, ZURIDAH H, SPENCER K, NG PP, KAMEL A G M. Molecular fingerprinting of fusidic acid- and rifampicin-resistant strains of methicillin-resistant *Staphylococcus aureus* (MRSA) from Malaysian hospitals, 1113
NORK M *see* ELLIS *et al.*, 70
NORRIS S J *see* MAGNARELLI *et al.*, 649
NUTIKKA A *see* HOEY *et al.*, 143

OBARO S, ADEGBOLA R. The pneumococcus: carriage, disease and conjugate vaccines, 98
OGATA Y *see* NARIOKA *et al.*, 687
OGAWA T *see* SUGIYAMA *et al.*, 27
OGUMA K *see* MAHMUT *et al.*, 286, 813
OHKURA K *see* GOTO *et al.*, 178
OHKUSA T *see* KOBAYASHI *et al.*, 305
OHNISHI K *see* TAKAHASHI *et al.*, 510
OHNISHI O *see* GOTO *et al.*, 178
OHNISHI Y *see* NARIOKA *et al.*, 687
OHTA T *see* MAEGAWA *et al.*, 34
OHTSUKA A *see* MAHMUT *et al.*, 286
OHYAMA T *see* MAHMUT *et al.*, 813
OKADA M, SODA Y, HAYASHI F, DOI T, SUZUKI J, MIURA K, KOZAI K. PCR detection of *Streptococcus mutans* and *S. sobrinus* in dental plaque samples from Japanese pre-school children, 443
OKAZAKI Y *see* KOGA *et al.*, 777
OKSI J *see* PANELIUS *et al.*, 731
OKUI T *see* NAGANO *et al.*, 405
OLIVA B *see* POURSHABAN *et al.*, 564
OLIVEIRA S C *see* LECLERQ *et al.*, 20
OLIVEIRA S C *see* ROSINHA *et al.*, 661
OLVER W J, STAFFORD J, CHEETHAM P, BOSWELL T C. Comparison of Candida ID medium with Sabouraud-chloramphenicol agar for the isolation of yeasts from clinical haematology surveillance specimens, 221
OÑATE A *see* SALGADO *et al.*, 771
ONDRUSOVA A *see* KRCMERY *et al.*, 110
OREFICI G *see* FATTORINI *et al.*, 1071
ORTONEDA M, PASTOR F J, MAYAYO E, GUARRO J. Comparison of the virulence of *Scedosporium prolificans* strains from different origins in a murine model, 924
OSAKI T, YAMAGUCHI H, TAGUCHI H, FUKADA M, KAWAKAMI H, HIRANO H, KAMIYA S. Interleukin-8 induction and adhesion of the coccoid form of *Helicobacter pylori*, 295
OSAKI T *see* TAGUCHI *et al.*, 336
OSTERHAUS A D M E *see* NIESTERS *et al.*, 695
OTOMO K *see* SUGAWARA *et al.*, 131
OYEDEJI K S *see* SMITH *et al.*, 851
OYSTON P C F *see* ATKINS *et al.*, 539
OYSTON P C F *see* JONES *et al.*, 1055

PAAVONEN J *see* WATSON *et al.*, 1021
PACIOREK J. Virulence properties of *Escherichia coli* faecal strains isolated in Poland from healthy children and strains belonging to serogroups O18, O26, O44, O86, O126 and O127 isolated from children with diarrhoea, 548
PAI K *see* KUMAR *et al.*, 832
PALAVECINO E *see* GARCÍA *et al.*, 530
PANAGIO L A, FELIPE I, VIDOTTO M C, GAZIRI L C J. Early membrane exposure of phosphatidylserine followed by late necrosis in murine macrophages induced by *Candida albicans* from an HIV-infected individual, 929
PANDEY H P *see* KUMAR *et al.*, 832

PANELIUS J, LAHDENNE P, HEIKKILÄ T, PELTOMAA M, OKSI J, SEPPÄLÄ I. Recombinant OspC from *Borrelia burgdorferi sensu stricto*, *B. afzelii* and *B. garinii* in the serodiagnosis of Lyme borreliosis, 731
PANELIUS J *see* HEIKKILÄ *et al.*, 641
PAS S D *see* NIESTERS *et al.*, 695
PASTOR F J *see* ORTONEDA *et al.*, 924
PATEL S *see* WHITING *et al.*, 837
PEARCE L *see* LIU *et al.*, 117
PEARSON G R *see* COOKSON *et al.*, 1032, 1041
PEARSON G R *see* WALES *et al.*, 755
PEDERSEN J *see* LIU *et al.*, 117
PEISACHOV M *see* SHENKMAN *et al.*, 747
PELLETIER R, LORANGER L, MARCOTTE H, DE CAROLIS E. Voriconazole and fluconazole susceptibility of *Candida* isolates, 479
PELTOMAA M *see* HEIKKILÄ *et al.*, 641
PELTOMAA M *see* PANELIUS *et al.*, 731
PENRICE G M *see* McGUIGAN *et al.*, 971
PERMAR S *see* ZHANG *et al.*, 42
PERRONE M *see* BERROTERAN *et al.*, 764
PERRY N T *see* CHART *et al.*, 522
PEVALOVA L *see* KRCMERY *et al.*, 110
PIETROBONO R *see* FATTORINI *et al.*, 1071
PIFFARETTI J-C *see* GUTACKER *et al.*, 123
PISARČÍKOVA M *see* KRCMERY *et al.*, 110
POIROT J L *see* SENDID *et al.*, 433
POPOVA M *see* BOYANOVA *et al.*, 786
POULAIN D *see* SENDID *et al.*, 433
POURSHABAN M, FERRINI A M, MANNONI V, OLIVA B, AURELI P. Transferable tetracycline resistance in *Listeria monocytogenes* from food in Italy, 564
POURSHAFIE M, GRIMONT F, KOHESTANI S, GRIMONT P A D. A molecular and phenotypic study of *Vibrio cholerae* in Iran, 392
PRIOR J *see* ATKINS *et al.*, 539
PRIOR R *see* ATKINS *et al.*, 539
PROBERT W *see* JANDA *et al.*, 575
PURGELOVÁ A *see* KRCMERY *et al.*, 110

QUE T-L *see* LAU *et al.*, 635
QUIROGA T *see* GARCÍA *et al.*, 530

RABERIN H *see* FLORI *et al.*, 871
RAHMAN M, MONIRA S, NAHAR S, ANSARUZZAMAN M, ALAM K, ALAM M, ALBERT M J. Tn *phoA* mutants of *Providencia alcalifaciens* with altered invasiveness of HEp-2 cells, 682
RAINBOW L, HART C A, WINSTANLEY C. Distribution of type III secretion gene clusters in *Burkholderia pseudomallei*, *B. thailandensis* and *B. mallei*, 374
RAMACHANDRAN V *see* BETTELHEIM *et al.*, 713
RAMSAY M E *see* TROTTER *et al.*, 855
RAO J R *see* XU *et al.*, 1117
RAOULT D *see* GREUB AND RAOULT, 915
RAZ P *see* MARRS *et al.*, 138
READ R C *see* HART *et al.*, 903
REZA-GHOLIZADEH M *see* SUGAWARA *et al.*, 131
RICHARDS M H *see* ROSEHART *et al.*, 1128
RIGGIO M P, LENNON A. Development of a PCR assay specific for *Peptostreptococcus anaerobius*, 1097
RISHI P *see* TIWARI *et al.*, 503
ROBEY M, MORGAN E, LODGE J M, BOLTON A J, MARTIN G D, BROWN N L, STEPHEN J. A new chromosomal locus associated with gut-modulated phenotypes in *Salmonella enterica* serotype Typhimurium, 247
RÔÇAS I N *see* SIQUEIRA *et al.*, 1090
RODRÍGUEZ J C *see* RUIZ GARCIA *et al.*, 273
ROE J M *see* COOKSON *et al.*, 1032, 1041
ROHANI M Y *see* NORAZAH *et al.*, 1113
ROMANI R *see* CONTINI *et al.*, 879
ROSEHART K, RICHARDS M H, BIDOCHKA M J. Microsatellite analysis of environmental and clinical isolates of the opportunist fungal pathogen *Aspergillus fumigatus*, 1128
ROSINHA G M S, MYIOSHI A, AZEVEDO V, SPLITTER G A, OLIVEIRA S C. Molecular and immunological characterisation of recombinant *Brucella abortus* glyceraldehyde-3-phosphate-dehydrogenase, a T- and B-cell reactive protein that induces partial protection when co-administered with an interleukin-12-expressing plasmid in a DNA vaccine formulation, 661
ROSINHA G M S *see* LECLERQ *et al.*, 20
ROYO G *see* RUIZ GARCIA *et al.*, 273
ROZGONYI F *see* KNAUSZ *et al.*, 187
RUBINSTEIN E *see* SHENKMAN *et al.*, 747
RUIZ GARCIA M, RODRÍGUEZ J C, NAVARRO J F, SAMPER S, MARTÍN C, ROYO G. Molecular epidemiology of tuberculosis in Elche, Spain: a 7-year study, 273
RUSSELL I *see* WATSON *et al.*, 1021
RUSSELL P *see* ATKINS *et al.*, 539
RUSSELL P *see* JONES *et al.*, 1055
RUSSLIES M *see* INCE *et al.*, 899

SAARINEN M, EKMAN P, HE Q, IKEDA M, VIRTALA M, YU D T Y, ARVILOMMI H, GRANFORS K. Elimination of *Salmonella enterica* serotype Enteritidis in intestinal epithelial cells by mechanisms other than nitric oxide, 13
SADLER F *see* TROTTER *et al.*, 855
SAITO A *see* ARAKAKI *et al.*, 159
SAITO Y *see* SUGAWARA *et al.*, 131
SAKAE K *see* MATSUMOTO *et al.*, 264
SAKAGUCHI Y *see* MAHMUT *et al.*, 286, 813
SAKASHITA H *see* TAKAHASHI *et al.*, 510
SALCEDO C *see* ALCALÁ *et al.*, 1102
SALEM A E *see* EL-MAHALLAWY *et al.*, 601
SALGADO F, GARCÍA A, OÑATE A, GONZÁLEZ C, KAWAGUCHI F. Increased in-vitro and in-vivo biological activity of lipopolysaccharide extracted from clinical low virulence *vacA* genotype *Helicobacter pylori* strains, 771
SALMON J E *see* BRAZIER *et al.*, 985
SALMON J E *see* JONES *et al.*, 978
SALMON J E *see* McGUIGAN *et al.*, 971
SALMON J E *see* McLAUCHLIN *et al.*, 990
SAMPER S *see* RUIZ GARCIA *et al.*, 273
SANTOS K R N *see* SIQUEIRA *et al.*, 1090
SARKIALA-KESSEL E *see* FORSBLOM *et al.*, 207
SATO K *see* KOGA *et al.*, 238, 777
SATO N *see* KUROSAWA *et al.*, 385
SATO N *see* TAKAHASHI *et al.*, 611
SAVION N *see* SHENKMAN *et al.*, 747
SAXEN H *see* HEIKKILÄ *et al.*, 641
SAXEN H *see* MARRS *et al.*, 138
SAZ J V *see* LLEDÓ *et al.*, 861
SCHALLER M, MAILHAMMER R, KORTING H C. Cytokine expression induced by *Candida albicans* in a model of cutaneous candidosis based on reconstituted human epidermis, 672
SEGALA D *see* CONTINI *et al.*, 879
SEJNOVÁ D *see* KRCMERY *et al.*, 110
SENDID B, POIROT J L, TABOURET M, BONNIN A, CAILLOT D, CAMUS D, POULAIN D. Combined detection of mannanaemia and anti-mannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic *Candida* species, 433
SEPPALA I *see* HEIKKILÄ *et al.*, 641
SEPPÄLÄ I *see* PANELIUS *et al.*, 731
SERACENI S *see* CONTINI *et al.*, 879
SERLUPI-CRESCENZI O *see* FATTORINI *et al.*, 1071
SHARMA A, KAUR R, GANGULY N K, SINGH P D, CHAKRABORTI A. Subtype distribution of *Haemophilus influenzae* isolates from North India, 399
SHARP L *see* HENDERSON *et al.*, 1013
SHENKMAN B, VARON D, TAMARIN I, DARDIK R, PEISACHOV M, SAVION N, RUBINSTEIN E. Role of *agr* (RNAIII) in *Staphylococcus aureus* adherence to fibrinogen, fibronectin, platelets and endothelial cells under static and flow conditions, 747
SHERMAN B A *see* MAGNARELLI *et al.*, 326
SHIH C-M, CHAO L-L. Genetic analysis of the outer surface protein C gene of Lyme disease spirochaetes (*Borrelia burgdorferi sensu lato*) isolated from rodents in Taiwan, 318
SHIMADA Y *see* KOGA *et al.*, 238
SHIN H-K *see* CHAE *et al.*, 417
SHIN K, YAMAUCHI K, TERAGUCHI S, HAYASAWA H, IMOTO I. Susceptibility of *Helicobacter pylori* and its urease activity to the peroxidase-hydrogen peroxide-thiocyanate antimicrobial system, 231
SHIN R, SUZUKI M, MORISHITA Y. Influence of intestinal anaerobes and organic acids on the growth of enterohaemorrhagic *Escherichia coli* O157:H7, 201
SHINA A, HART C A, STENTON M D, DAWSON S, McCRACKEN C M, BINNS S H, GASKELL R M, WINSTANLEY C. Distribution of *fim3* and *flaA* TTGE sequence types amongst isolates of *Bordetella bronchiseptica* from different host animals, 557
SHINOHARA C *see* YAMADA *et al.*, 1080
SHINOZAWA Y, MATSUMOTO T, UCHIDA K, TSUJIMOTO S, IWAKURA Y, YAMAGUCHI K. Role of interferon-gamma in inflammatory responses in murine respiratory infection with *Legionella pneumophila*, 225
SIITONEN A *see* MARRS *et al.*, 138
SIMMONDS P. TT virus infection: a novel virus-host relationship, 455
SIMMONDS R S *see* BALAKRISHNAN *et al.*, 941
SINGH P D *see* SHARMA *et al.*, 399
SIQUEIRA J F, RÔÇAS I N, DE UZEDA M, COLOMBO A P, SANTOS

K R N. Comparison of 16S rDNA-based PCR and checkerboard DNA–DNA hybridisation for detection of selected endodontic pathogens, 1090
ŚLUSARCZYK J *see* AUGUSTYNOWICZ *et al.*, 169
SMITH D G E *see* HOEY *et al.*, 143
SMITH S I, KIRSCH C, OYEDEJI K S, ARIGBABU A O, COKER A O, BAYERDÖFFER E, MIEHLKE S. Prevalence of *Helicobacter pylori vacA*, *cagA* and *iceA* genotypes in Nigerian patients with duodenal ulcer disease, 851
SMITH-PALMER A, STEWART J, FYFE L. Inhibition of listeriolysin O and phosphatidylcholine-specific production in *Listeria monocytogenes* by subinhibitory concentrations of plant essential oils, 567
SMITS H L *see* GASEM *et al.*, 173
SODA Y *see* OKADA *et al.*, 443
SOMSEL P *see* MARRS *et al.*, 138
SOSROSENO W, HERMINAJENG E. The role of macrophages in the induction of murine immune response to *Actinobacillus actinomycetemcomitans*, 581
SPENCE R P, TOWNER K J, HENWOOD C J, JAMES D, WOODFORD N, LIVERMORE D M. Population structure and antibiotic resistance of *Acinetobacter* DNA group 2 and 13TU isolates from hospitals in the UK, 1107
SPENCER K *see* NORAZAH *et al.*, 1113
SPLITTER G A *see* ROSINHA *et al.*, 661
SRIPRAKASH K S, HARTAS J, WHITE A. Antibodies to streptococcal inhibitor of complement function and M peptides in a post-streptococcal glomerulonephritis endemic region of Australia, 589
STAFFORD J *see* OLVER *et al.*, 221
STARY A *see* WATSON *et al.*, 1021
STENTON M D *see* SHINA *et al.*, 557
STEPHEN J *see* ROBEY *et al.*, 247
STEPHENS P *see* HILL *et al.*, 949
STEWART J *see* SMITH-PALMER *et al.*, 567
STOCK I, HENRICHFREISE B, WIEDEMANN B. Natural antibiotic susceptibility and biochemical profiles of *Yersinia enterocolitica* -like strains: *Y. bercovieri*, *Y. mollaretii*, *Y. aldovae* and '*Y. ruckeri*', 56
ST-PIERRE Y *see* GAUTHIER *et al.*, 192
STRAY PEDERSON B *see* WATSON *et al.*, 1021
STRINGARO A *see* FATTORINI *et al.*, 1071
SUGAWARA I, UDAGAWA T, HUA S C, REZA-GHOLIZADEH M, OTOMO K, SAITO Y, YAMADA H. Pulmonary granulomas of guinea-pigs induced by inhalation exposure of heat-treated BCG Pasteur, purified trehalose dimycolate and methyl ketomycolate, 131
SUGAWARA S *see* SUGIYAMA *et al.*, 27
SUGAWARA S *see* UEHARA *et al.*, 626
SUGIYAMA A, UEHARA A, IKI K, MATSUSHITA K, NAKAMURA R, OGAWA T, SUGAWARA S, TAKADA H. Activation of human gingival epithelial cells by cell-surface components of black-pigmented bacteria: augmentation of production of interleukin-8, granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor and expression of intercellular adhesion molecule 1, 27
SUNDAR S *see* KUMAR *et al.*, 832
SUN Z *see* ZHANG *et al.*, 42
SUZUKI J *see* OKADA *et al.*, 443
SUZUKI M *see* MATSUMOTO *et al.*, 264
SUZUKI M *see* SHIN *et al.*, 201
SUZUKI T *see* KOBAYASHI *et al.*, 305
SUZUKI Y *see* MATSUMOTO *et al.*, 264
SYED Q *see* McLAUCHLIN *et al.*, 1001
SZOVENYOVÁ Z *see* KRCMERY *et al.*, 110

TABOURET M *see* SENDID *et al.*, 433
TAGG J R *see* BALAKRISHNAN *et al.*, 941
TAGUCHI H, TAKAHASHI M, YAMAGUCHI H, OSAKI T, KOMATSU A, FUJIOKA Y, KAMIYA S. Experimental infection of germ-free mice with hyper-toxigenic enterohaemorrhagic *Escherichia coli* O157:H7, strain 6, 336
TAGUCHI H *see* OSAKI *et al.*, 295
TAKADA H *see* SUGIYAMA *et al.*, 27
TAKADA H *see* UEHARA *et al.*, 626
TAKAHASHI K *see* KOGA *et al.*, 238, 777
TAKAHASHI M *see* TAGUCHI *et al.*, 336
TAKAHASHI T, ENDO T, NAKAMURA T, SAKASHITA H, KIMURA K, OHNISHI K, KITAMURA Y, IWAMOTO A. Dihydrofolate reductase gene polymorphisms in *Pneumocystis carinii* f. sp. *hominis* in Japan, 510
TAKAHASHI T, GOTO M, ENDO T, NAKAMURA T, YUSA N, SATO N, IWAMOTO A. *Pneumocystis carinii* carriage in immunocompromised patients with and without human immunodeficiency virus infection, 611
TAKAKURA N *see* WAKABAYASHI *et al.*, 844
TAKENOUCHI T *see* KOGA *et al.*, 238
TAKIZAWA T *see* KOBAYASHI *et al.*, 305
TALBERT R L *see* NASH *et al.*, 105
TALLMAN P *see* MARRS *et al.*, 138
TAMARIN I *see* SHENKMAN *et al.*, 747
TAMATE N *see* NAGANO *et al.*, 405
TAMURA Y *see* WAKABAYASHI *et al.*, 844
TAN T Y. A comparison of PCR detection of *mecA* with two standard methods of oxacillin disk susceptibility testing for coagulase-negative staphylococci, 83
TASHIRO S *see* NARIOKA *et al.*, 687
TATEYAMA M *see* ARAKAKI *et al.*, 159
TAY L *see* WANG AND TAY, 710
TAYLOR-ROBINSON A W, TAYLOR-ROBINSON D. Evaluation of liquid culture media to support growth of *Mobiluncus* species, 491
TAYLOR-ROBINSON D, FURR P M. Observations on experimental colonisation of mice by ureaplasmas of human origin, 866
TAYLOR-ROBINSON D *see* TAYLOR-ROBINSON AND TAYLOR-ROBINSON, 491
TEMPLETON A *see* WATSON *et al.*, 1021
TENG J L-L *see* WOO *et al.*, 740
TERAGUCHI S *see* SHIN *et al.*, 231
TERAGUCHI S *see* WAKABAYASHI *et al.*, 844
TESTERMAN T L *see* McGEE *et al.*, 958
THOMAS D W *see* HILL *et al.*, 949
THOMSON R P M *see* McLAUCHLIN *et al.*, 1001
THURUTHYIL S J *see* ZHU *et al.*, 1063
TIEMER B *see* INCE *et al.*, 899
TITBALL R W *see* ATKINS *et al.*, 539
TIWARI R P, DEOL K, RISHI P, GREWAL J S. Factors affecting haemolysin production and Congo red binding in *Salmonella enterica* serovar Typhimurium DT 98, 503
TOKIMATSU I *see* KARASHIMA *et al.*, 423
TOLEDO M S *see* FIGUEROA *et al.*, 300
TOMBAZZI C *see* BERROTERAN *et al.*, 764
TOWNER K J *see* SPENCE *et al.*, 1107
TRAN MANH SUNG R *see* FLORI *et al.*, 871
TRONCOSO M *see* FIGUEROA *et al.*, 300
TROTTER C L, FOX A J, RAMSAY M E, SADLER F, GRAY S J, MALLARD R, KACZMARSKI E B. Fatal outcome from meningococcal disease – an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin, 855
TSILMAN B *see* LEJBKOWICZ *et al.*, 90
TSOI H-W *see* WOO *et al.*, 740
TSUJI T *see* MAHMUT *et al.*, 813
TSUJIMOTO S *see* SHINOZAWA *et al.*, 225
TSUNE I *see* KUROSAWA *et al.*, 385

UCHIDA K *see* SHINOZAWA *et al.*, 225
UCHIDA K *see* WAKABAYASHI *et al.*, 844
UCHIYAMA Y *see* NAGANO *et al.*, 405
UDAGAWA T *see* SUGAWARA *et al.*, 131
UEHARA A *see* SUGIYAMA *et al.*, 27
UEHARA A, SUGAWARA S, TAKADA H. Priming of human oral epithelial cells by interferon-γ to secrete cytokines in response to lipopolysaccharides, lipoteichoic acids and peptidoglycans, 626

VÄISÄNEN M-L *see* FORSBLOM *et al.*, 207
VALSANGIACOMO C *see* GUTACKER *et al.*, 123
VAN BELKUM A. Molecular typing of micro-organisms: at the centre of diagnostics, genomics and pathogenesis of infectious diseases?, 7
VANDAMME P *see* MAHENTHIRALINGAM *et al.*, 533
VANDAMME P *see* VERMIS *et al.*, 937
VARON D *see* SHENKMAN *et al.*, 747
VÁZQUEZ J A *see* ALCALÁ *et al.*, 1102
VERMIS K, COENYE T, MAHENTHIRALINGAM E, NELIS H J, VANDAMME P. Evaluation of species-specific *recA*-based PCR tests for genomovar level identification within the *Burkholderia cepacia* complex, 937
VIDOTTO M C *see* PANAGIO *et al.*, 929
VILLEMUR R *see* GAUTHIER *et al.*, 192
VIRTALA M *see* SAARINEN *et al.*, 13

WAKABAYASHI H, TAKAKURA N, YAMAUCHI K, TERAGUCHI S, UCHIDA K, YAMAGUCHI H, TAMURA Y. Effect of lactoferrin feeding on the host antifungal response in guinea-pigs infected or immunised with *Trichophyton mentagrophytes*, 844
WALES A D, CLIFTON-HADLEY F A, COOKSON A L, DIBB-FULLER M P, LARAGIONE R M, PEARSON G R, WOODWARD M J. Production of attaching-effacing lesions in ligated large intestine loops of 6-month-old sheep by *Escherichia coli* O157:H7, 755
WALES A D *see* COOKSON *et al.*, 1032, 1041

WANG D *see* LIU *et al.*, 76
WANG S X, TAY L. Early identification of *Mycobacterium tuberculosis* complex in BACTEC cultures by ligase chain reaction, 710
WANG X *see* MAEGAWA *et al.*, 34
WARD J M *see* HENDERSON *et al.*, 1013
WATANABE T *see* MAHMUT *et al.*, 813
WATSON E J, TEMPLETON A, RUSSELL I, PAAVONEN J, MARDH P-A, STARY A, STRAY PEDERSON B. The accuracy and efficacy of screening tests for *Chlamydia trachomatis* : a systematic review, 1021
WATSON R *see* ELLIS *et al.*, 70
WEEKS S *see* WELKOS *et al.*, 821
WELKOS S, FRIEDLANDER A, WEEKS S, LITTLE S, MENDELSON I. In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody, 821
WHIPP M *see* BETTELHEIM *et al.*, 713
WHITE A *see* SRIPRAKASH *et al.*, 589
WHITE M *see* ENGELICH *et al.*, 484
WHITING G C, EVANS J T, PATEL S, GILLESPIE S H. Purification of native α-enolase from *Streptococcus pneumoniae* that binds plasminogen and is immunogenic, 837
WIEDEMANN B *see* STOCK *et al.*, 56
WILCOX M H *see* ASHA *et al.*, 891
WILLCOX M D P *see* ZHU *et al.*, 1063
WILLSHAW G A *see* CHART *et al.*, 1050
WILSON M *see* HENDERSON *et al.*, 1013
WILSON M J *see* HILL *et al.*, 949
WINSTANLEY C. Spot the difference: applications of subtractive hybridisation to the study of bacterial pathogens, 459
WINSTANLEY C *see* HART *et al.*, 903
WINSTANLEY C *see* RAINBOW *et al.*, 374
WINSTANLEY C *see* SHINA *et al.*, 557
WOLLE K, LEODOLTER A, MALFERTHEINER P, KÖNIG W. Antibiotic susceptibility of *Helicobacter pylori* in Germany: stable primary resistance from 1995 to 2000, 705
WONG S S-Y *see* WOO *et al.*, 740
WOO P C-Y, LEUNG K-W, TSOI H-W, WONG S S-Y, TENG J L-L, YUEN K-Y. Thermo-tolerant *Campylobacter fetus* bacteraemia identified by 16S ribosomal RNA gene sequencing: an emerging pathogen in immunocompromised patients, 740
WOO P C-Y *see* LAU *et al.*, 635
WOODFORD N *see* SPENCE *et al.*, 1107
WOODWARD M J *see* COOKSON *et al.*, 1032, 1041
WOODWARD M J *see* WALES *et al.*, 755
WREN B W *see* ZHANG *et al.*, 495
WRIGHT P A *see* CHART *et al.*, 522
XU J, RAO J R, MILLAR B C, ELBORN J S, EVANS J, BARR J G, MOORE J E. Improved molecular identification of *Thermoactinomyces* spp. associated with mushroom worker's lung by 16S rDNA sequence typing, 1117
YAMADA H *see* SUGAWARA *et al.*, 131
YAMADA M, NAKAE H, YUMOTO H, SHINOHARA C, EBISU S, MATSUO T. *N* -Acetyl-D-galactosamine specific lectin of *Eikenella corrodens* induces intercellular adhesion molecule-1 (ICAM-1) production by human oral epithelial cells, 1080
YAMADA T *see* KOBAYASHI *et al.*, 305
YAMAGATA E *see* KARASHIMA *et al.*, 423
YAMAGUCHI H *see* OSAKI *et al.*, 295
YAMAGUCHI H *see* TAGUCHI *et al.*, 336
YAMAGUCHI H *see* WAKABAYASHI *et al.*, 844
YAMAGUCHI K *see* SHINOZAWA *et al.*, 225
YAMAKAMI Y *see* KARASHIMA *et al.*, 423
YAMAUCHI K *see* SHIN *et al.*, 231
YAMAUCHI K *see* WAKABAYASHI *et al.*, 844
YAMAZAKI M *see* MATSUMOTO *et al.*, 264
YANO S *see* NAGANO *et al.*, 405
YAP E H *see* LIU *et al.*, 76
YAP E P H *see* LIU *et al.*, 76
YOKOTA K *see* MAHMUT *et al.*, 286, 813
YOUNG K A *see* ALLAKER *et al.*, 312
YU D T Y *see* SAARINEN *et al.*, 13
YUEN K-Y *see* LAU *et al.*, 635
YUEN K-Y *see* WOO *et al.*, 740
YUMOMOTO H *see* YAMADA *et al.*, 1080
YUSA N *see* TAKAHASHI *et al.*, 611
YUSUF E *see* BRAZIER *et al.*, 269
ZHANG L *see* MARRS *et al.*, 138
ZHANG Y, PERMAR S, SUN Z. Conditions that may affect the results of susceptibility testing of *Mycobacterium tuberculosis* to pyrazinamide, 42
ZHANG Z-W, DORRELL N, WREN B W, FARTHING M J G. *Helicobacter pylori* adherence to gastric epithelial cells: a role for non-adhesin virulence genes, 495
ZHU H, THURUTHYIL S J, WILLCOX M D P. Determination of quorum-sensing signal molecules and virulence factors of *Pseudomonas aeruginosa* isolates from contact lens-induced microbial keratitis, 1063
ZURIDAH H *see* NORAZAH *et al.*, 1113